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2D    Two-dimensional 
3D    Three-dimensional 
ASTM   American Society for Testing and Materials 
BCLC    Barcelona Clinic Liver Cancer 
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DSA    Digital subtraction angiography 
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FOV    Field of view 
Gd   Gadolinium 
Gd-BOPTA   Gadolinium-gadobenate dimeglumin 
Gd-DOTA   Gadolinium- 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid 
GE    Gradient echo 
GRAPPA   Generalized Autocalibrating Partially Parallel Acquisition 
GW    Guidewire 
GWs   Guidewires 
Gy    Gray 
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I. ZUSAMMENFASSUNG  
 
Hintergrund 
Magnetresonanztomographie (MR)-gesteuerte endovaskuläre Interventionen bieten aufgrund 
des Fehlens ionisierender Strahlung, der Möglichkeit einer dreidimensionalen (3D) 
Bildakquisition und eines ausgezeichneten Weichteilkontrasts, zahlreiche Vorteile gegenüber 
der konventionellen Röntgenfluoroskopie. Das aktuell größte Hindernis bei der Durchführung 
endovaskulärer MR Interventionen ist der Mangel an geeigneten Instrumenten. Kommerziell 
erhältliche metallische Führungsdrähte und Katheter sind aufgrund ihrer Leitfähigkeit im MR 
Feld und ihrer potentiellen Radiofrequenz (RF) Erhitzung als MR-unsicher einzustufen. In der 
präklinischen Phase unserer Studie (Teil 1) wurden daher verschiedene interventionelle 
Instrumente an drei vaskulären Phantomen in einem 1,5 Tesla (T) MR Feld evaluiert zwecks 
der zukünftigen Anwendung zur intraarteriellen (i.a.) transkatheter MR-Angiographie 
während einer transarteriellen Chemoembolisation (TACE) (Teil 2). Eine anatomisch 
unerwartete arterielle Tumorversorgung kann im Rahmen einer TACE zur fehlgeleiteten 
Chemotherapie und unzureichender Behandlung des Tumors führen. Ziel der Studie war die 
Evaluation der zusätzlich zur TACE durchgeführten i.a. MR-Angiographie im Hinblick auf 
einen diagnostischen und auch therapeutischen Gewinn. 
 
Material und Methoden 
Teil 1: Das Auftreten von Suszeptibilitätsartefakten in drei Gradientenechosequenzen (GE) 
und einer Turbo-Spin-Echo-Sequenz wurde für 13 Katheter  an zwei verschiedenen 
vaskulären Modellen ausgewertet. Zudem wurden zwei MR-kompatible Prototypen von  
Führungsdrähten auf Suszeptibilitätsartefakte und RF-Erhitzung in vaskulären Modellen 
sowie in menschlichen Kadavern getestet. Die als MR-tauglich eingestuften Instrumente 
wurden im Rahmen des klinischen Teils der Studie angewendet. 
Teil 2: Bei 27 Patienten wurden 62 TACE mit i.a. transkatheter MR-Angiographie kombiniert 
durchgeführt. Zunächst wurde der Katheter unter Fluoroskopiekontrolle in die Tumor 
10 Zusammenfassung  
 
 
 
 
versorgende Arterie gesteuert. Kontrastgestützte i.a. transkatheter MR-Angiographie (10 ml 
Gadolinium-DOTA 5.0% Dotarem, Guerbet, Frankreich) wurde in der arteriellen, 
portalvenösen und spätvenösen Phase durchgeführt. Hierfür wurden zwei GE Sequenzen 
(FLASH 3D, VIBE, Siemens Magnetom Aera 1,5T) eingesetzt um die Tumorperfusion zu 
evaluieren. Die Bilder wurden qualitativ durch zwei Radiologen ausgewertet. Die quantitative 
Auswertung erfolgte über die „region of interest“ (ROI) Analyse. Signal- und Kontrast-
Rausch-Verhältnis (SNR- und CNR) für FLASH 3D und VIBE Sequenzen wurden mit dem 
Mann-Whitney-Test verglichen. 
 
Ergebnisse 
Teil 1: Gleitbeschichtete 4 und 5 French (F) Katheter (Terumo, Tokio, Japan) verursachten 
keine Artefakte in den gewählten Sequenzen und wurden während des klinischen Teils der 
Studie benutzt. MR-kompatible Führungsdrähte waren zum Zeitpunkt der Experimente in der 
präklinischen Phase noch nicht zur Verwendung am Menschen zugelassen.  
Teil 2: Die i.a. transkatheter  MR-Angiographie bestätigte die korrekte Katheterpositionierung 
in 53/62 (85%) Interventionen und führte zur Katheterrepositionierung in drei Fällen. Eine 
zusätzliche arterielle Tumorversorgung wurde in sechs Fällen nachgewiesen. Neue Herde 
wurden in vier Fällen identifiziert. Die quantitative Analyse der SNR im Tumor ergab eine 
Überlegenheit der VIBE Sequenz (arterielle Phase: Median 36,96 [Minimum 9,92 - Maximum 
91,54], portalvenöse Phase: 28,59 [10,48 - 83,89], spätvenöse Phase: 24,37 [10,21 - 72,28]) 
gegenüber der FLASH 3D Sequenz (arterielle Phase: 21,36 [7,79 - 50,11], portalvenöse 
Phase: 20,25 [5,50 - 57,87], spätvenöse Phase: 16,19 [5,83 - 51,03], p-Werte: 0,02, 0,01 und 
0,002). Der Vergleich der CNR ergab keine signifikanten Unterschiede (alle p > 0,05). 
 
Schlussfolgerung 
Gleitbeschichtete Katheter (Terumo, Tokyo, Japan) sind in der von uns genutzten MR-
Umgebung MR-kompatibel und sind als sicher während endovaskulärer Verfahren 
11 Zusammenfassung  
 
 
 
 
einzustufen. Die i.a. transkatheter MR-Angiographie bei TACE ermöglicht die Visualisierung 
der Kathetersposition und hilft eine fehlerhafte oder unzureichende Tumorembolisation zu 
verhindern. Die VIBE Sequenz erzielt eine höhere SNR aber keine verbesserte CNR 
verglichen mit der FLASH 3D Sequenz. 
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II. ABSTRACT 
 
Background 
Endovascular interventions in magnetic resonance (MR) offer potential benefits like lack of 
ionizing radiation, three-dimensional (3D) imaging or soft tissue contrast, compared to other 
techniques. The main hurdle in performing MR interventions is the lack of appropriate 
devices. Regular guidewires (GWs) and catheters cause conductivity and potential 
radiofrequency (RF) heating due to their metallic components. Consequently, they are 
considered MR unsafe. In the preclinical phase of the study (part 1) we evaluated potentially 
MR compatible interventional devices in vascular phantoms at 1.5 Tesla (T).  Our aim was to 
study their future application during transarterial chemoembolization (TACE) complemented 
with intraarterial (i.a.) transcatheter MR angiography (part 2). The usefulness of i.a. 
transcatheter MR angiography during TACE was evaluated.  
 
Materials und Methods 
Part 1: Several experiments with 13 catheters on two different vasculars models were 
conducted. The occurrence of susceptibility artifacts was evaluated in three gradient echo 
(GE) sequences and one turbo spin echo (TSE) sequence. MR compatible prototypes of 
GWs were tested for artifact size and RF heating in vascular models as well as in human 
cadaver. Devices qualified as MR compatible were used during the clinical part of the study.  
Part 2: Overall, 27 patients with hepatocellular carcinoma (HCC) underwent 62 TACE 
procedures combined with i.a. transcatheter MR angiography. Prior to embolization a 
catheter was guided by X-ray fluoroscopy into the HCC supplying artery. Contrast-enhanced 
i.a. transcatheter MR angiography (10 ml Gadolinium-DOTA 5.0% Dotarem, Guerbet, 
France) was performed in arterial, portalvenous and late venous phase using either three-
dimensional fast low angle shot (FLASH 3D) or volume interpolated breath hold (VIBE) 
sequences (Siemens Magnetom Aera 1.5T) to study tumor perfusion. The images were 
evaluated qualitatively by two radiologists. Quantitative evaluation was performed using the 
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region of interest (ROI) analysis. Signal and contrast to noise ratios (SNR and CNR) for 
FLASH 3D and VIBE sequences were compared by Mann-Whitney test.   
 
Results 
Part 1: Several 4 and 5 French (F) catheters with hydrophilic coating (Terumo, Tokyo, Japan) 
caused no artifacts in applied sequences and were employed during the clinical part of the 
study. MR compatible GWs were by the time of our experiments in the preclinical phase of 
research and their use in patients was not permitted.  
Part 2: I.a. transcatheter MR angiography confirmed correct catheter positioning in 53/62 
(85%) procedures. Additional collateral tumor vascularization was detected in six cases. New 
lesions were identified in four patients during this procedure. Quantitative analysis of SNR in 
tumor demonstrated that the VIBE sequence (arterial: median 36.96 [range: 9.92 - 91.54], 
portalvenous: 28.59 [10.48 - 83.89] and late venous: 24.37 [10.21 - 72.28]) is superior to the 
FLASH 3D (arterial: 21.36  [7.79 - 50.11], portalvenous: 20.25 [5.50 - 57.87] and late venous 
phase: 16.19 [5.83 - 51.03], p values: 0.02, 0.01 and 0.002 respectively). The comparison of 
CNR yielded no significant differences (all p > 0.05).  
 
Conclusion 
Catheters with hydrophilic coating are safe when used at 1.5 T MR field during endovascular 
procedures. I.a. transcatheter MR angiography during TACE enables visualization of the 
catheter position and may prevent erroneous/insufficient tumor embolization. VIBE-sequence 
achieves a superior SNR but not CNR as compared to FLASH 3D. 
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III. INTRODUCTION 
 
III.1 Vascular interventions and imaging in MR 
Interventional radiology is a rapidly expanding field due to its minimal invasiveness. 
Apart from biopsies or drainages, endovascular techniques are especially successful. 
Stenotic or occluded vessels, bleedings, vessels malformations or tumors can be treated 
under X-ray guidance. Since these interventions require X-ray guidance (fluoroscopy or CT-
guidance), they trigger discussions about potential risks of ionizing radiation exposure. 
Indeed, a retrospective study published recently in Lancet (59) shows a clear association 
between exposure to a high radiation dose in childhood and increased occurrence of 
leukemia or brain cancer in the maturity. In this study the authors analyzed 283.919 CT 
scans in children under 15 years old and demonstrated that cumulative ionizing radiation of 
~50 miligrey (mGy) (5-10 CT body scans) triples the occurrence of leukemia while dosage of 
~60 mGy (2-3 CT head scans) can triple the occurrence of brain tumors in adulthood (59). 
The radiation doses during fluoroscopy depend on procedure length and may vary from 4.0 
milisievert (mSv) in simple biliary drainage up to 49.5 mSv in more complicated transjugular 
intrahepatic portosystemic shunt (TIPS) (16). As a matter of principle, radiation exposure of 
the patient should be kept to minimum and if possible other imaging methods should be 
preferred. Brenner et al. (7) stated that the potential risk of inducing cancer due to ionizing 
radiation varies and depends on life expectancy of the individual. Hence, radiation exposure 
to physicians regularly performing interventions should be kept to a minimum. The mean 
natural radiation dose for a human being is 2.4 mSv per year (19) and additional radiation 
dose has to be strictly monitored. Another issue in fluoroscopy guided procedures is the 
need for contrast media, that if applied in high doses, especially in patient with impaired renal 
function (58), may lead to contrast induced nephropathies (3, 53). Considering the above-
mentioned drawbacks, magnetic resonance imaging (MRI) has the potential to overcome 
most of these problems. 
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  MRI is a relatively novel technique that provides anatomical and functional 
information superior to fluoroscopy and to CT. The discovery of MR is related to the Nobel 
Prize awarded in 1952 to Felix Bloch and Edward Purcell, who independently discovered the 
MR phenomenon in 1946. The first prerequisites were established much earlier: the 
mathematical transformation needed for MRI was discovered by the Napoleon’s chief 
engineer, Jean Baptiste Joseph Fourier, in the 19th century. Nevertheless, the possibility of 
exploitation of magnetic resonance in imaging appeared for the first time in 1960 when the 
first MR scanner prototypes were built. Paul Lauterbur, a chemistry professor at the 
University of New York, set the foundation for MR imaging by performing an image formation 
on small tube samples in MR and introduced the use of gradients in the static magnetic field. 
Terms like slice selection, active magnetic shielding, gradient coils or echo planar imaging 
(EPI) were developed by Sir Peter Mansfield in the late 70’s. Eventually the noninvasive MR 
imaging method of human internal tissues was possible and P. Lauterbur together with Sir P. 
Mansfield received in 2003 the Nobel Prize for their work. Although MRI has undergone 
many advances over the past years, the basic principle remains the same. Briefly, this 
technique is based on resonant effects of protons of hydrogen atoms that build up to 80% of 
the human body. Energy that is emitted by the MR scanner in form of radio waves interacts 
with the protons of hydrogen nuclei. Receiver coils deliver the signal that is subsequently 
transformed by a computer system and used to produce the detailed images of the human 
body. Specific sequences of RF pulses and switching of the gradients define the signal 
magnitude. Investigations in the field of MRI were performed in the 80’s and 90’s of the last 
century however  the topic of interventional MRI (iMRI) is still emerging. Not only lack of 
ionizing radiation but also possibility to delineate between diseased and healthy tissue, 3D 
imaging, excellent soft tissue contrast, multiplanar scan capabilities as well as use of non-
iodized contrast agents in low doses make MRI a desirable technique in guidance of 
interventional radiology. To date biopsies and drainages under MR guidance are well-
established procedures. MR guidance of endovascular procedures is more demanding and is 
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still a challenge in clinical MR application. To date, numerous investigations have 
demonstrated the feasibility of endovascular stenting (11,28), balloon angioplasty (12), vena 
cava filter placement (43) or heart valve implantation (38) in animal trials. Lack of MR 
compatible and simultaneously safe devices remains the largest hurdle for clinical 
investigations. Indeed, conventional guidewires (GWs) or catheters are not MR safe and 
generate eddy currents due to conductivity of their metallic components. Currently available 
implants, on the other hand, although not always hazardous, induce distortions of the 
magnetic field that renders their localization on MR images impossible. On this account, 
several business concerns have developed MR compatible and safe devices; the prototypes 
are by now available for clinical research.  
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III.2 Interventional MR scanners 
The MR scanner consists of a magnet that creates a static magnetic field. 
Radiofrequency transmitter produces and receiver coils register the signal. Magnetic field 
gradients are applied to localize the signal. The scanners dedicated to interventional MRI 
were developed in the first half of 1990 and differ substantially from regular ones. These 
specific scanners have to fulfill the need of facilitated patient access. The first dedicated 
system, which was introduced in 1994, was characterized by a vertical gap between two 
magnets termed “double doughnut” (66). The operator could stand between two halves of the 
magnet and this way perform interventions with his hand on the patient who was placed in 
the isocenter of the MR field. Some tradeoffs however restricted utility of these scanners. For 
example, the 58 cm gap between the magnets was too tight for some surgeons, the 0.5 T 
field strength ranged in the midfield sector with reduced imaging capabilities compared to 1.5 
T high field magnets. Moreover, most of the surgical and anesthetic instruments were not 
even MR compatible and most certainly not MR safe at that time. Therefore low safety of the 
procedures, difficult cooperation between anesthesia, surgery and radiology teams confined 
the practicability and profitability of these early devices. Current interventional MR scanners 
focus more on advancing the MR sequences dedicated to MR guided procedures than on 
patient’s access. Our institution (Clinic of diagnostic and interventional radiology, Homburg, 
Germany) is equipped with an MR scanner with 1.5 T (Magnetom Aera, Siemens, Erlangen, 
Germany) with 70 cm wide MR bore; this scanner is in close proximity to an angiography 
suite with just 3.7 meter in between both rooms (Figure 1). 
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MR room 
 
Angiography  
room 
3,7 m 
Figure 1  
Layout of the 1.5 T MR scanner used for vascular interventions in close proximity to an 
angiography suite in the Clinic of Diagnostic and Interventional Radiology, Saarland 
Medical Center, Homburg, Germany. 
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III.3 MRI Sequences in interventional procedures  
The strategy of acquiring MR images during the interventional procedures differs from 
the one used in the diagnostic MRI. In particular, image acquisition time has to be much 
shorter to allow steering of interventional instruments (63). Visualization of interventional 
devices and anatomy with a frame rate of approximately ten images per second without 
losing image quality is the most crucial feature. However, due to the physics of MRI the 
increase of imaging speed is accompanied by loss of spatial resolution. Sequences like 
steady state free precession (SSFP) or fast low angle shot (FLASH) are most often in use for 
MR guided interventions. In currently available MR scanners, SSFP image with a matrix of 
128 x 128 mm can be achieved in approximately 0.4 second (65). Moreover, this technique 
allows the delineation of blood vessels without application of contrast agent (65). FLASH 
allows a rapid acquisition of T1 weighted images and if applied after injection of T1 
shortening contrast agent offers vessel accentuation in MR angiography (32). Current 
interventional MR scanners offer the opportunity to manipulate scan parameters inside the 
scanner room and to observe the images on an in-room monitor. Sequences applied for 
angiography examinations in our institution were by the time of the study: three-dimensional 
FLASH (FLASH 3D) and volumetric interpolated breath hold (VIBE) sequences. The latter 
one a modified FLASH 3D sequence with the advantage of depicting soft tissue around the 
vessel and not the vessel only. 
 
III.3.1 Signal to noise ratio (SNR) and contrast to noise ratio (CNR) 
Signal to noise ratio (SNR) is a commonly used parameter to investigate the quality of 
MR images (36). In brief, the signal is measured as the mean pixel intensity in the region of 
interest (ROI) (39.). The noise, in turn, is determined as the standard deviation (SD) of pixel 
intensity in the free air on an image (39). The recently developed parallel imaging technique, 
enhancing the speed of image acquisition has however an impact on calculating SNR. This 
technique is frequently used in FLASH 3D and volume interpolated breath hold (VIBE) 
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sequences, which were applied in our study. The major drawback of parallel imaging is a 
reduction of SNR due to decreased number of phase encoding steps. The loss of SNR in 
sequences using parallel imaging is approximately equal to the square root of the 
accelerating factor used (22). The so called ‘g’ factor is an additional downside of parallel 
imaging, which has an impact on SNR. The ‘g’ factor reflects an increase in local noise and is 
dependent on coil geometry, the orientation of phase-encoding direction, acceleration factor 
and the field of view as well as on the examined object (61). Its value may be calculated 
within pre-scan images (39). However, the GRAPPA (Generalized Autocalibrating Partially 
Parallel Acquisition (31)) algorithm affects the calculation of g factor and it may no longer be 
valid (67). The SNR measurements in parallel imaging techniques differ from regular 
calculation methods in conventional images due to a different estimation of noise. In 
conventional images, noise distribution follows the Gauss distribution and the noise is 
“spread” evenly across the image (54). In parallel imaging the noise distribution is 
inhomogeneous across the acquired image and follows the Rayleigh distribution (22). In 
some cases however obtaining the Gauss distribution is possible when the noise is 
estimated from the difference of the two images with high signal (67). Therefore two images 
have to be subtracted and the noise is determined as the SD of pixel intensity in the same 
ROI where the signal was measured in an unsubtracted image (18,62). The signal is 
proportional to the voxel size, the larger the voxel the higher the signal. The size of the voxel 
however is also depended on additional factors like field of view (FOV), number of phase 
encoding steps and slice thickness (ST) (36). In order to perform and compare the valid SNR 
measurements all above mentioned parameters must remain equal in sequences applied in 
different patients. 
Contrast to noise ratio (CNR) has greater potential in determining the image quality 
than SNR (39,57). It is defined as the difference between the signal intensity of two different 
tissues (measured by ROI) to standard deviation of noise (39,57). In other words it is the 
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SNR difference between two different tissues divided by SD of noise. Both values (SNR and 
CNR) contribute to the objective image quality.  
The exact equations applied in calculation of SNR and CNR are illustrated in the 
chapter (VI.1.6 Quantitative analysis). 
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III.4 Instrument Visualization in MR environment 
The visualization of instruments differs in diverse imaging techniques. Excellent 
contrast between the instrument and surrounding tissue in X-ray can be obtained through the 
use of high-atomic number metals, which provide high attenuation of X-rays and render the 
instrument visible with high resolution. MR visualization of instruments is much more 
demanding and can be divided into passive and active (20). Interventional instruments can 
be detected inside the human body, which consists mainly of water molecules, by producing 
a signal void. This appears dark against the brighter tissue signal in the MR image. If the 
devices are made from metal or have metal components, they will cause an additional signal 
void due a susceptibility artifact. The susceptibility artifact is caused by local field 
inhomogeneity of the static magnetic field, which destroys the signal in this area. Local 
susceptibility artifacts can however be used to localize instruments (17). This is called 
passive visualization and makes the instrument directly visible as part of the standard MR 
image. Robustness, safety and simplicity are the main advantages of passive techniques. In 
the case of susceptibility markers material with high susceptibility (i.e., dysprosium oxide, 
iron oxide) is embedded into the instrument (i.e., catheter or guide wire) and produces a 
signal void. The drawback of this technique involves different marker sizes, which may be too 
large to depict them in detail in small vessels, or otherwise too small in larger vessels. In the 
case of positive markers, MR contrast agents based on gadolinium are effective since they 
can create a positive contrast when applied in the correct concentration (73). The general 
principle of this method consists of T1 time shortening by gadolinium derivatives. The minor 
drawback is that T1 weighted sequences have to be used to exploit this effect.  
The active technique usually requires interaction between the instrument and the MR 
scanner. A microcoil, which is specially designed and tuned for this purpose, is fixed at the 
tip of the device and electronically connected to the scanner. The signal if the microcoil – and 
therefore the tip of the device – can be localized using projection data sets (20). The position 
of the device/microcoil can be projected on previously acquired image and the motion of the 
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instrument can be visualized (20). In cases of the patient’s motion or sudden kinking of the 
vessel the simultaneous acquisition of microcoil position and the anatomic background is 
required (12). The main limitation of active tracking technique is the need for conductive 
wires, which may cause hazards for the patient due to the excessive heating of the tissues.  
 
III.4.1 Guidewires 
Guidewires (GWs) represent an essential tool for vascular interventions. Special type 
of guidewire (GW) was introduced in the beginning of the 80’s by Terumo (Terumo, Tokyo, 
Japan) company. Its core is made of nitinol, a metal alloy mainly consisting of nickel and 
titanium. The term nitinol originates from these two metals and the place of origin (Naval 
Ordnance Laboratory, Maryland, USA) and is a finding of a Metallurgist William Buehler and 
Frederick Wang (1962) who were investigating a material that could be used in dismantling 
magnetic mines. Nitinol is non-ferromagnetic, superelastic and highly biocompatible and 
therefore it is widely used in production of hydrophilic GWs. Though not ferromagnetic, the 
metal core of nitinol GWs is conductive and therefore can act as an antenna during MRI. This 
may lead to substantial heating, which is a potential safety problem of nitinol GWs (56). Thus 
novel ideas concerning the manufacturing and construction of MR compatible wires were 
presented.  
 
III.4.2 Catheters 
Catheters can be used for various procedures in different anatomic regions with the 
help of various forms of tips and different fabrics employed during the manufacturing 
process. To achieve sufficient stiffness, many catheters have the so-called braiding, i.e., a 
metal mesh strengthens the body of the catheter. Most often, its made of stainless steel, 
which prompts the radiopacity. At the same time it makes those catheters unsuitable for the 
MR environment due to susceptibility artifacts and potential heating (30, 42, 56). Thus some 
catheters, especially the shorter ones, are built without any braiding. Those (pure plastic) 
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catheters are inherently safe in the MR environment. The non-braided catheters are however 
difficult to depict on an MR image due to their small size. For this reason and better passive 
navigation local metal markers can be placed along the shaft (2).   
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III.5 Safety aspects in MR environment 
Static magnetic field strength of 9.4 T or less, which is currently applied in the 
diagnostic MR scanners, is considered not to pose any significant risk for humans. 
Nonetheless, the magnetic field can be dangerous especially when any metallic objects are 
brought close to the magnet field. Pacemakers or deep brain stimulator wires, as well as 
GWs and catheters used in endovascular procedures in interventional radiology, can be 
harmful to the human body due to their excessive heating and conductive properties (23, 35). 
Ferromagnetic implants can change their position in the human body while being placed in 
the magnetic field and thereby cause damage to surrounding organs. Electrical and non-
electrical hospital equipment that regularly accompanies intensive care unit patients presents 
another safety issue since the magnetic field can cause their malfunctioning and they can be 
drawn in to the MR scanner.  
 
III.5.1 Interventional instruments 
As mentioned above, the hazards concerning placing metallic objects in the magnetic 
field are well known. According to Maxwell’s theory, the temperature can arise from eddy 
currents induced by radiofrequency (RF) pulses and from induction loops build for example 
from electrocardiographic electrodes (23, 35, 42). In such cases there is no storage of 
electrical energy within the device (42). The energy however is cumulated when excessive 
heating is evoked around and within conductors (i.e., GWs or catheters) by resonating waves 
along them (42). If resonance of the GW occurs, the reflected waves are spreading along the 
longitudinal axis of the wire, which acts like a dipole antenna. In such scenario forming of 
standing RF waves is possible (42). The occurrence of resonance and hence the heating of a 
GW exposed to RF pulses depends on its position in a MR scanner, length, and if examined 
in a solution, on its immersed length (76). For example in the 1.5T MR scanner, the 
excessive heating hazard occurs when conductors longer then 15 - 18 cm are used (76). 
According to theoretical models, it can be assumed that the GWs shorter than a quarter of 
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the wavelength (i.e., 10.75 cm at 1.5 T) should be MR safe (76). The moment of occurrence 
of the resonance phenomenon is however troublesome to predict since it depends also on 
environmental factors (i.e., patient’s weight, room temperature, etc.) and not only on the wire 
itself.  
The paper of Nitz et al.(56) explains in detail the theory of coupling of wires with the 
MR field induced by a transmitter coils and heating effects at the ends of such a conductor. 
The authors performed several experiments with a standard nitinol GW (Terumo, Tokyo, 
Japan), that was placed in different positions (in and off center) of the MR scanner and 
suspended in the air as well as immersed in a saline solution filled phantom imitating the 
patient’s tissue. The temperature alteration during real time gradient echo (GE) sequences 
was obtained by optical fiber temperature system (56). The results demonstrate that the 
voltage spreads towards both ends of a wire and the further the wire from the magnet 
isocenter the greater the temperature increase at the tip (56). The very relevant discovery is 
that the temperature increases also as a function of wire length and raised about 2°C in 170 
cm and about 6°C in 156 cm wires. Since the temperature alterations were also observed at 
the tip of the wire inside the phantom (56), they could be potentially harmful to the patient.  
Hence, standard GWs cannot be used to perform endovascular MR guided interventions. Of 
note, in one of the studies sparks were observed at a distal tip of a standard GW as a mark 
of excessive heating (13).  
 
 III.5.2 Contrast media and intraarterial contrast agent application 
Contrast media used in MR consist mainly of paramagnetic chelates of gadolinium 
(Gd) and are necessary in about 50% of MR examinations. The gadolinium-based contrast 
media increase the signal intensity on T1-weighted images by reduction of T1 relaxation 
time.  Usually Gd-based contrast agents are applied intravenously and sometimes 
intraarticularly. The intraarterial (i.a.) application of MR contrast media, although performed in 
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several studies (29, 46) is performed off label. It is to assume that the kinetics after i.a. 
administration are similar to i.a. application of iodinated contrast agents.  
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III.6 Role of interventional radiology in the therapy of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death 
after lung and stomach cancer in poor developed countries and fifth after colorectal, breast 
and pancreas cancer in high developed countries (6). The incidence of HCC increases with 
advancing age in all populations in Europe (25). Most frequent risk factors, except from 
cirrhosis, include hepatitis C virus (HCV) (approximately 70% in Europe) and hepatitis B virus 
(HBV) (approximately 70% in east Asia and Africa). Among causes of cirrhosis and severe 
liver fibrosis the main factor encompasses increased alcohol uptake, non-alcoholic 
steatohepatitis (NASH) and inherited disorders like morbus Wilson, hemochromatosis or alfa-
1-antitrypsin deficiency. It has been estimated that one third of individuals with liver cirrhosis 
will develop HCC during their lives (64). Additional risk factors include also nicotine abuse 
(71), diabetes (24) and obesity (51). The role of radiology is emphasized in the surveillance 
of cirrhotic and high-risk groups of patients, as well as in monitoring of disease stages with 
ultrasound, CT and MRI. In particular interventional radiology is highlighted in loco-regional 
treatment of moderate and advanced stages of HCC with radiofrequency ablation (RFA), 
transarterial chemoembolization (TACE), transarterial embolization (TAE) or selective 
internal radiation therapy (SIRT).  
TACE is a recommended therapy method of choice in the intermediate stage of HCC 
without extrahepatic spread or vessel invasion (8, 9). Commonly it is also applied as a 
bridging therapy before liver transplantation or as a down-staging method before liver 
resection in HCC patients. Randomized controlled trials demonstrated that TACE achieves 
undeniable survival benefits in properly qualified patients as compared to best supportive 
care and it can prolong the survival up to 20 months (49) in the B stage according to 
Barcelona Clinic Liver Cancer (BCLC) criteria. The procedure itself is characterized by slow 
injection of chemotherapeutic agent (Doxorubicin, Cisplatin or/and Mitomycin C) and oily 
emulsion of iodinated contrast agent (Lipiodol), which has an embolic effect. This leads to 
tumor necrosis due to clotting of smaller tumor feeding vessels and results in delivery of the 
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chemotherapeutic agent directly to the HCC. Due to the tumor supply by hepatic artery 
vessels high doses of chemotherapy can be delivered to the tumor with relatively low 
systemic effects.  
Camma et al. (15) found in their metaanalysis that segmental or subsegmental 
application of chemotherapy yields better treatment response in comparison to the 
embolization of the whole liver lobe. The HCC lesions due to its high arterial vessel supply is 
usually well recognizable in digital subtraction angiography (DSA). In some cases, if the 
tumor is atypically hypovascularised or after numerous previous TACE therapies, the lesion 
might not be visible under fluoroscopy. This may contribute to incorrect position of the 
catheter during application of chemotherapy and future poor therapy outcome. Catheters 
used to cannulate the celiac trunk have the diameters from 4F to 5F. Commonly used 
catheter shapes are cobra or sidewinder configurations. Selecitve and superselective 
cannulation of hepatic vessels is usually performed by smaller microcatheters (2.4F - 2.9F). 
In some cases larger catheters with hydrophilic coating suffice for this purpose.  
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IV STUDY OUTLINE 
 
This study consists of two parts. The first part of the study focuses on determining the 
MR safe interventional instruments and on their validation in vascular models in a 1.5 T MR 
field. The devices characterized as MR safe and MR compatible are then applied in the 
second part of the study, which evaluates the liver tumor perfusion by i.a. transcatheter 
magnetic resonance angiography during transarterial chemoembolization in patients with 
hepatocellular carcinoma. The specific aims of each part are described below in section IV.1 
and IV.2. 
 
IV.1. SPECIFIC AIMS OF PART 1: MR safety of interventional instruments and their 
validation in vascular models 
Transcatheter embolization is usually performed in an angiography suite only. The 
interventional instruments applied are mostly not MR safe due to their long metallic 
components, which may induce potentially harmful RF heating. The MR angiography part of 
the study requires however MR compatible and safe devices. Appropriate interventional 
instruments, like GWs or catheters especially designed for MR were not commercially 
available. Therefore we aimed to determine the potential use of novel prototypes of MR 
compatible GWs, which by that time were in the preclinical research phase. Before starting 
the clinical part of the study our aim was also to investigate the safety of instruments, 
regularly applied during TACE procedures in a 1.5 T MR scanner in a vessel model.  
 
In this part of the study we aimed to answer the following question: 
1. Does the novel prototype of MR compatible GW cause any increased heating in 
1.5T MR filed as compared to a standard nitinol GW? 
2. Is the novel prototype of MR compatible GW clearly visible on GRE MR 
images potentially applied during MR interventions? 
31 Study outline 
 
 
 
 
3. Which catheters cause no artifacts on the MR image, due to lack of any 
metallic material incorporated and therefore are inherently MR safe? 
 
IV.2. SPECIFIC AIMS OF PART 2: Evaluation of liver tumor perfusion by intraarterial 
transcatheter magnetic resonance angiography during transarterial  
chemoembolization in patients with hepatocellular carcinoma  
The aim of this part of the study was to evaluate the liver tumor perfusion by i.a. 
transcatheter MR angiography during TACE in patients with HCC. The unexpected vascular 
supply or neoangiogenesis of the tumor may hamper TACE success and the unselective 
application of the chemoembolic agents may contribute to treatment-related liver failure 
(50,68). We aimed to investigate if MR angiography after transcatheter i.a. contrast agent 
application offers a possibility to identify the treated liver parenchyma. We hypothesized that 
this method can allow visualization of potentially new vascularisation or newly formed 
metastases or not perfused areas, that suggest tumor supply from another, extrahepatic 
collateral vessel. Hence, the interventional radiologist can change the primary therapy 
position of the catheter before final treatment, which may be significant for optimal tumor 
targeting.  
 
In this part of the study we aimed to answer the following questions: 
1. Is the performance of i.a. MR angiography during TACE feasible? 
2. What is the optimal contrast agent concentration for i.a. MR angiography perfusion? 
3. Which sequence is appropriate for i.a. perfusion studies: VIBE or FLASH 3D? 
4. What are the benefits of i.a. transcatheter MR angiography during TACE? 
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V. PART 1: MR SAFETY OF INTERVENTIONAL INSTRUMENTS AND THEIR  
VALIDATION IN VASCULAR MODELS 
 
V.1 Heating experiments with standard and MR compatible guidewires  
V.1.1 Aorta model 
V.1.1.1 Objectives 
Several in vitro and animal trials using nitinol GWs have demonstrated excessive 
heating in the MR environment, rendering these devices unsafe for endovascular use (42, 
56). A new MR compatible and MR safe GW has been developed recently (40, 41). We 
aimed to compare heating effects of this new MR compatible, polyetheretherketone (PEEK) 
GW with nitinol GW (Terumo, Japan) during different scenarios in MR imaging of a phantom. 
 
V.1.1.2 Materials and Methods 
The first 100 cm of the nitinol (Terumo, Tokyo, Japan) and MR compatible PEEK GW 
(Epflex, Dettingen, Germany) of the same length and diameter (145 cm, 0.89 mm) were 
immersed in a saline filled phantom (rubber tubes with 8 mm inner diameter, 2.4 mm wall 
thickness, Figure 2). The probes of a fiber-optic thermometer (Fotemp 4, OPTOcon AG, 
Dresden, Germany) were attached to the tip of the GWs with a thin thread. One of the probes 
(called reference probe) was also attached to the MR table as a reference probe for the 
temperature in the MR room. The accuracy of the measuring device was ± 0.2° Celsius (C). 
The aorta bifurcation of the phantom was exactly in the middle of a multichannel coil, which 
was wrapped around the phantom. The GW tip was placed 3 cm above the aorta bifurcation 
in all experiments. Balanced steady state free precession (bSSFP) (TE 1.6 milisecond (ms); 
time of repetition (TR) 3.5 ms; flip angle (FA) 60°; field of view (FOV) 40 cm; matrix 256 x 
256) and spoiled gradient echo (SPGR) (time to echo (TE) 1.8 ms; TR 60 ms; FA 60°; FOV 
40 cm; matrix 256 x 256) pulse sequences were acquired in a 1.5 T MR scanner with use of 
an 8-channel array coil (GE Medical Systems, Waukesha, WI, USA). Temperatures were 
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recorded with 1 second (s) temporal resolution while the phantom was placed centrally in the 
bore of MR scanner and in an off-center position (x = 24 cm,  
y = -5 cm, z = -10/10 cm). The bSSFP sequence was run for 1 minute and the SPGR 
sequence for 12 minutes. The estimated specific absorption rate (SAR) for every sequence 
equaled 1.15 W/kg. The peak SAR for every sequence equaled 2.30 W/kg.  
 
Guidewires 
MR compatible guidewire  
A novel PEEK GW (Epflex, Dettingen, Germany) of 0.89 mm diameter and 145 cm 
length was examined.  The GW consists of PEEK and Pebax tip with 3 iron-oxide markers 
(“MagnaFy“, Nano4imaging, Aachen, Germany) integrated into the tip and 3 markers behind 
the tip. The markers allow passive visualization due to the creation of susceptibility artifacts.  
 
Nitinol-based guidewire 
A nitinol GW (Terumo, Tokyo, Japan) was used as comparison. The GW has a nitinol 
alloy core. The core is moreover covered with tungsten in a polyurethane jacket to create 
radiopacity under X-ray fluoroscopy. A hydrophilic coating provides gliding properties. The 
same diameter and length as in the MR compatible GW were selected (0.89 mm diameter, 
145 cm length).  
 
 
 
 
 
 
Figure 2 
Aorta shaped phantom with nitinol-based 
GW, black arrow is pointing a GW. 
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V.1.1.3 Results 
bSSFP sequence acquisition for 60 seconds 
In the first scenario, when the nitinol GW was placed in the isocenter of a 1.5T MR 
scanner during a 60 seconds bSSFP sequence, only minor temperature changes of both 
GWs were observed. The temperature of the nitinol GW increased from initially 20.3°C to a 
maximum of 20.6 °C (Figure 3). Temperature changes within the measurement error of the 
fiber-optic thermometer (± 0.2°C) of 0.1°C were observed for the PEEK GW. The reference 
probe attached to the MR scanner table did not change the temperature (20.3 °C).   
The second position in the MR scanner, when the aorta phantom was placed 
eccentrically close to the MR scanner walls, was performed to simulate the worst case 
scenario for possible heating. The temperature of a nitinol GW in this off-center position rose 
from initial 20.3°C to 29.9°C (Figure 4). The PEEK GW demonstrated no relevant 
temperature elevation. The reference probe demonstrated a minimal increase of temperature 
of 0.1°, which was within the measurement error interval of the fiber-optic thermometer  
(± 0.2°C).  
  
SPGR acquisition for 720 seconds 
The second sequence, i. e. the SPGR, was run continuously for 720 seconds (i. e. 12 
minutes) in order to imitate the duration of imaging during the endovascular intervention. 
Results of these experiments are presented in Figure 5 and Figure 6. As demonstrated in 
Figure 5, during 720 seconds the temperature at the nitinol GW tip increased from 20.3°C to 
21.4°C when the phantom was placed centrally in the magnet bore. The PEEK GW 
demonstrated a maximum temperature elevation of 0.4°. The reference probe showed a 
temperature increase from 20.4°C up to 20.8°C. Both temperature changes of PEEK GW 
and the reference probe were within the measurement error of the fiber-optic thermometer  
(± 0.2°C).  
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The off-center position demonstrated the temperature increase for the nitinol GW from 
21.8°C to 34.8°C (Figure 6). The same experiment repeated with the MR compatible PEEK 
GW demonstrated a temperature elevation of 0.1°. The reference probe showed an increase 
from 21.2°C to 21.3°C.  
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Figure 3  
Nitinol GW (yellow) and MR compatible PEEK GW 
(red) imaged with bSSFP sequence for 60 seconds in 
in center position. 
Figure 4  
Nitinol GW (yellow) and MR compatible PEEK GW 
(red) in bSSFP sequence for 60 seconds in off center 
position. 
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Figure 5  
Minor temperature fluctuation of nitinol GW (yellow) 
comparing to PEEK GW (red) during SPGR imaging 
for 12 min in in center position in the scanner. 
 
Figure 6 
The 13° temperature elevation of nitinol GW (yellow) 
comparing to minor temperature variations of the 
PEEK GW (red) during SPGR imaging for 12 min in off 
center position  in the scanner. 
 
37 Part 1: MR safety of interventional instruments and their validation in vascular... 
 
 
 
 
V.1.1.4 Conclusions 
The temperature of the nitinol GW increased by 0.3°C (center) and 1.1°C (off-center 
position) while use of the bSSFP and by 9.6°C and 13°C (off-center position) while use of the 
SPGR sequence. Only minor temperature changes up to a maximum of 0.4°C were 
observed with the MR compatible PEEK GW in any applied position or sequence. The 
prototype of a MR compatible PEEK GW shows substantially lower heating than a standard 
nitinol GW in bSSFP or SPGR imaging sequences in a phantom. The novel PEEK GW 
demonstrated a potential for endovascular MR interventions due to the lack of heating during 
the procedure.  
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V.1.2 Thiel embalmed human cadaver and vascular phantom 
V.1.2.1 Objectives 
The aim of this study was to measure a heating temperature while retracting a nitinol 
based GW in a saline filled phantom and in the vessels of a Thiel embalmed human cadaver 
to find the maximal RF-heating due to resonance effect. The near-real time MR imaging as 
continuously run SPGR sequence was applied in 1.5 T MR Scanner (Signa HDxt, GE 
Healthcare Systems, USA). The local ethics committee approval was obtained before 
starting the experiments. To check the cooling effect of a blood flow we simulated similar 
conditions in the femoral artery of a human cadaver with saline solution.  
 
V.1.2.2 Materials and Methods 
A 0.89 mm nitinol-based GW with a length of 145 cm (Terumo, Tokyo, Japan) was 
immersed over the length of 85 cm in a 260 ml saline filled phantom. The probes of fiber-
optic thermometer (Fotemp 4, OPTOcon AG, Dresden, Germany) were attached to the tip, 
20 cm from the proximal end and to the distal end of the GW. One reference probe was 
attached to the MR table. Initial temperature of all probes was 20.9°C. The accuracy of the 
measuring device was ±0.2°C. The temperature changes of a nitinol GW were recorded 
while running a SPGR sequence (TR 60 ms; TE 1.8 ms; FA 60°; FOV 40 cm; matrix 256 x 
256) for 5 minutes. Then the nitinol GW was retracted 2 cm every 10 seconds while running 
the same sequence for another 5 minutes. Only one temperature probe was attached to the 
tip of the GW in the human cadaver experiment. The Terumo GW was placed under X-ray 
guidance in the left common iliac artery with initial tip temperature of 21.5°C. The GW was 
retracted with the same speed as previously while running the same sequence and 
temperature was recorded. Afterwards the GW was placed again in the left femoral artery 
and the measurements were taken after inducing a saline flow of 1.6 ml/s. All temperature 
curves were recorded with 1s temporal resolution. Experimental setups are summarized in 
Table 1. 
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Phantom Cadaver 
Saline filled (260 ml) Artificially induced saline flow 
1.6 ml/s, GW in the left iliac 
artery 
Initial temperature 20.9°C Initial temperature 20.9°C 
Fiber-optic thermometer probes: 
- GW tip 
- 20 cm from proximal end 
- end of a GW 
Fiber-optic thermometer probes: 
- GW tip 
FLASH sequence for 5 min FLASH sequence for 5 min 
Retracting a GW every 10 sec Retracting a GW every 10 sec 
Table 1 
Experimental setup of a GW heating analysis in a phantom and cadaver. 
 
V.1.2.3 Results  
The results are summarized in Table 2. The maximum temperature increase of the 
nitinol GW observed in the phantom study without retraction of the GW was from 20.9°C to 
24.9°C measured at the GW tip. The highest temperature of 25.4°C was observed in the 
probe attached 20 cm from the proximal GW end in the phantom experiment with retraction. 
The temperature of a Terumo GW did not show a relevant change in the iliac vessel 
(maximum 22.8°C without flow or retracting and 23.1°C with flow retracting respectively). The 
cooling effect of saline flow showed no relevant influence on the temperature changes of the 
nitinol GW which increased by 2.2° with and by 2° without retracting a GW.  
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Experiment number 
 
Experimental setup in different scenarios 
 
Experiment 1 
Aorta phantom without retraction 
Max. temperature at: 
tip of a GW 20 cm from 
the prox. 
End of a 
GW 
End of a 
GW 
 
24.90°C 21.60°C 24.70°C 
 
Experiment 2 
Aorta phantom with retraction 
Max. temperature at: 
tip of a GW 20 cm from 
the prox. 
End of a 
GW 
End of a 
GW 
 
24.40°C 25.40°C 21.20°C 
 
Experiment 3 
Thiel-embalmed human cadaver without 
flow or retraction 
Max. temperature at: 
tip of a GW - - 
 
22.80°C - - 
 
Experiment 4 
Thiel-embalmed human cadaver with 
saline flow and without retraction 
Max. temperature at: 
tip of a GW - - 
 
23.00°C - - 
 
Experiment 5 
Thiel-embalmed human cadaver with 
saline flow and with retraction 
Max. temperature at: 
tip of a GW - - 
 
23.00°C - - 
 
Table 2 Nitinol-based GW in different scenarios in 1.5T MR scanner.  
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V.1.2.4 Conclusions 
Retraction of the GW in a vessel model and in Thiel-embalmed human cadaver did 
not have any significant influence on the measured temperature in our experiments. 
Nonetheless, it is not possible to conclude that all GWs are MR safe. Conditions creating 
resonance and consequently substantial heating might still occur for electrically conducting 
wires and instruments (26). Artificially induced saline flow in a vessel of a human cadaver did 
not show any substantial cooling effect on nitinol GW independent on retraction procedure, 
but this might be due to the relatively low increase in temperature during our experiments 
even without flow.  
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V.2 Artifact size of a new MR compatible guidewire prototype depends on time to echo 
in gradient echo sequences 
 
V.2. 1 Objectives 
As mentioned before, lack of appropriate devices hinders the endovascular 
interventions under MR guidance. GWs composed of nickel and titanium alloys or stainless 
steel were proven to be unsafe and not fully MR compatible due to RF heating, which is 
caused by their conductive properties. Glass fibers embedded in epoxy resin are considered 
to be a metal free alternative in a novel GW (MaRVis, Aachen, Germany). To enable the 
passive visualization under MR guidance special iron-oxide markers are immersed at the tip 
and along the GW core. GE sequences generally cause greater artifacts as compared to spin 
echo (SE) sequences. However, MR guidance of vascular interventions is usually performed 
by GE sequences. Aim of this study was to test the passive visualization of the novel MR 
compatible GW (MaRVis, Aachen, Germany) by GE FLASH 3D sequence using different TE 
times in 1.5 T MR scanner (Aera, Siemens Medical, Erlangen, Germany).  
     
V.2.2 Materials and Methods 
A flexible type of a novel MR compatible GW (MaRVis, Aachen, Germany), with the 
diameter of 0.89 mm and length of 145 cm was tested in a glass made, aorta shaped 
phantom. The phantom was made of thin glass and was immersed in a water bath with 
diluted MR contrast agent (1.0% Gadolinium-gadobenate dimeglumin (Gd-BOPTA), 
Multihance® (Bracco, Milan, Italy)). The GW were immersed by approximately 1/2 of its 
length (Figure 7). The GW was imaged with straight configuration in the main lumen of the 
aorta and curved into the right renal artery. Different TE from 1.07 to 20 ms was employed 
during the FLASH 3D GE sequence (TR 4.89 - 21.85 ms [shortest TR depending on TE], 
FOV 400 mm, matrix 512 x 101, ST 0.8 mm, FA 25°, number of slices 5). Obtained images 
were evaluated according to the artifact size of the GW.  
43 Part 1: MR safety of interventional instruments and their validation in vascular... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V.2.3 Results 
The artifact size depends strongly on applied time to echo (TE) and increases with 
the echo time. The best passive visualization (defined as smallest GW artifact) was achieved 
with the minimal TE of 1.07 ms for both GWs. TE greater than 10 ms hinders the recognition 
of the GW core due to interference of the markers in both GW types and obstructs the 
visibility of the 5 mm diameter renal artery of the aorta phantom. There were no differences 
in visualization between the stiff and flexible GWs. The images of GW are presented in the 
Figures 8-9. Please note that depending on TE time TR varies from 4.89 ms with TE 1.07 
ms to TR 21.85 ms with TE 20 ms. 
  
Inserted GW 
Figure 7  
Aorta shaped model in a saline bath.  
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V.2.4 Conclusions 
The markers used in the GW make passive visualization possible applying a FLASH 
3D GE sequence. As expected, the lowest achievable TE was the best for depicting both 
GWs. The novel MR compatible GW is excellent depicted with low TE in GE sequences.     
 
 
  
Figure 8 
MaRVis flexible GW 0.89 mm, 145 cm straight  depicetd in the aorta phantom with the tip 
of the GW directly below the right renal artery. White arrow points to a GW. 
Figure 9  
MaRVis flexible GW 0.89 mm, 145 cm straight positioned in the aorta phantom with the tip 
of the GW above the right renal artery. White arrow points to a GW. 
 
 TE 1.07    TE2 ms     TE3 ms       TE4 ms      TE5 ms       TE6 ms        TE10 ms    TE20 ms 
 TE 1.07     TE2 ms     TE3 ms       TE4 ms      TE5ms      TE6ms     TE10 ms      TE20ms 
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V.3 Passive visualization of catheters in a vascular model  
 
V.3.1 Objectives 
Catheters and GWs are essential equipment in every angiography suite. Different 
types of catheters have different braiding (i.e., a metal mesh), which provides the desired 
rigidity, pushability and make them visible under fluoroscopy. This braiding prevents artifact-
free visibility under MR guidance and causes potential harm to the patient due to RF heating. 
Aim of this study was to evaluate the visibility and test the MR compatibility of 13 different 
angiographic catheters in vitro in two vessel models.  
 
V.3.2 Materials and Methods 
Thirteen regular catheters from Cook Medical (Bloomington, USA), Terumo (Tokyo, 
Japan) and Optimed Alta Flow Measuring catheters (Ettlingen, Germany) company with 
length of 65 and 100 cm, external diameter of 4F and 5F and differently shaped tip (cobra, 
straight, shepherd hook, pigtail, sidewinder) as well as 3 different microcatheters (Terumo, 
Tokyo, Japan and Cook Medical, Bloomington, USA) with diameters of 2.4F, 2.7F and 2.8F 
were tested. All catheters were first tested in a vessel model (Elastrat, Geneva, Switzerland, 
Figure 10) filled with 0.9% saline solution mixed with 1.0% of Gd-BOPTA, Multihance® 
(Bracco, Milan, Italy). The financial support for the model was assured by IIIOS Project (The 
Integrated Interventional Imaging Operating System (IIIOS) project funded by the European 
Community’s Seventh Framework Programme (FP7/2007 -2013) under Grant Agreement no 
238802). The first model consists of two parts, the femoral and the tibial one and a 3 liter 
fluid tank connected to the phantom. The specially designed introducer (Figure 11) allows 
insertion of a sheath through a silicon pad. The GWs and catheters are inserted through 
commercially introducer sheaths of 5F (Radifocus, Terumo, Tokyo, Japan). The diameters of 
each vessel respond the normal anatomic diameters of the vessels. The flow within the 
model is generated by a pump, which is located within the water tank. Then the catheters 
46 Part 1: MR safety of interventional instruments and their validation in vascular... 
 
 
 
 
were tested in glass-made, aorta-shaped model used in previous experiment (chapter V.2, 
Figure 7). Three T1 weighted GE sequences and one T2 weighted FSE sequence were 
applied (sequence1 GE FLASH two-dimensional (2D): TR 127 ms, TE 5.36 ms, FA 70°, ST 8 
mm, matrix 736 x 467; sequence2 GE FLASH 3D: TR 3.41 ms, TE 1.3 ms, FA 25°, ST 2 mm, 
matrix 512 x 448; sequence3 VIBE: TR 3.73 ms, TE 1.21 ms, FA 12°, ST 4 mm, matrix 320 x 
147; sequence 4 TSE T2 weighted: TR 3.690 ms, TE 85 ms, FA 180°, ST 10 mm, matrix 768 
x 468). All experiments were performed on a 1.5 T MR scanner (Aera, Siemens Medical, 
Erlangen, Germany) using the body array coil. 
  
 
 
 
 
 
 
 
  
Femoral box Tibial box 
 
3 liter tank and pump 
Figure 10  
Vessel model of the left lower extremity (Elastrat, Geneva, Switzerland).  
White silicon with inserted catheter 
Figure 11  
Introducer in the vessel model of the left lower extremity (Elastrat, Geneva, Switzerland). 
Femoral  and tibial vessels 
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V.3.3 Results 
All images are summarized in Tables 3-11. Catheters with hydrophilic coating from 
Terumo company (5F and 4F Cobra of 65 and 100 cm length as well as 5F Sidewinder of 
100 cm length), demonstrated no significant artifacts and good visualization of the shaft and 
tip without blurring effect, in particular in the aorta shaped glass phantom (Tables 3-6) and 
also in the Elastrat vessel model (Table 7). The TSE T2 weighted sequence was the most 
sensitive in depicting the catheters. The 4F catheters (Alta Flow Measuring catheters family: 
straight and pigtail like, Optimed, Ettlingen, Germany) demonstrated also no susceptibility 
artifacts (Tables 8 and 9). The Progreat microcatheters 2.4F, 2.7F and 2.8F (Terumo, Tokyo, 
Japan) demonstrated no susceptibility artifacts during imaging in either of the applied 
sequences, the 2.8F Cantata microcatheter (Cook Medical, Bloomington, USA) showed 
however a substantial susceptibility artifact along the entire shaft, making the catheter not 
recognizable (Table 10). The latter five commercially available catheters (Cook Medical, 
Bloomington, USA) with differently shaped tips (5F cobra 100 cm, 4F straight 65 cm, 4F 
pigtail 65 cm, 5F sidewinder 100 cm, 5F shepard hook 65 cm) demonstrated major 
susceptibility artifacts probably due to their double braiding with metal mesh from stainless 
steel (Table 11). Among latter catheters the 4F Pigtail 65 cm and 5F Sidewinder 100 cm 
showed substantially less artifacts at 15 cm distal section, the rest of the shaft demonstrated 
artifacts even larger than the iliac vessels of the aorta model.  
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Catheter type 
Sequence type:  
FLASH 2D 
4F Cobra 65 and 100 cm 
 
5F Cobra 65 and 100 cm 
 
5F Sidewinder 100 cm 
 
 
 
 
 
Table 3  
Cobra 4F, 5F and 5F sidewinder (Terumo, Tokyo, 
Japan) in aorta shaped model filled with saline and 1% 
Gd-BOPTA (Multihance, Bracco, Milan, Italy) solution. 
FLASH 2D sequence. 
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Catheter type 
Sequence type:  
FLASH 3D 
4F Cobra 65 and 100 cm 
 
5F Cobra 65 and 100 cm 
 
5F Sidewinder 100 cm 
 
 
Table 4 
Cobra 4F, 5F and 5F sidewinder (Terumo, Tokyo, 
Japan) in aorta shaped model filled with saline and 1% 
Gd-BOPTA (Multihance, Bracco, Milan, Italy) solution. 
FLASH 3D sequence. 
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Catheter type Sequence type: VIBE 
4F Cobra 65 and 100 cm 
 
5F Cobra 65 and 100 cm 
 
5F Sidewinder 100 cm 
 
 
Table 5 
Cobra 4F, 5F and 5F sidewinder (Terumo, Tokyo, 
Japan) in aorta shaped model filled with saline and 1% 
Gd-BOPTA (Multihance, Bracco, Milan, Italy) solution. 
VIBE  sequence. 
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Catheter type 
Sequence type: TSE  
T2 weighted 
4F Cobra 65 and 100 cm 
 
5F Cobra 65 and 100 cm 
 
5F Sidewinder 100 cm 
 
 
 
 
Table 6  
Cobra 4F, 5F and 5F sidewinder (Terumo, Tokyo, 
Japan) in aorta shaped model filled with saline and 1% 
Gd-BOPTA (Multihance, Bracco, Milan, Italy) solution. 
TSE T2 weighted sequence. 
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Catheter type Sequence type 
   FLASH 2D   FLASH 3D     VIBE 
 
  TSE 
  T2 weighted 
4F Cobra 65 
and 100 cm 
    
5F Cobra 65 
and 100 cm 
    
5F Sidewinder 
100 cm 
    
 
 
 
 
 
 
 
 
 
Table 7 
Cobra 4F, 5F and 5F sidewinder (Terumo, Tokyo, Japan) in vessel phantom, placed in the 
left superficial artery (Elastrat, Geneva, Switzerland) filled with saline and 1% Gd-BOPTA 
(Multihance, Bracco, Milan, Italy) solution. FLASH 2D, FLASH 3D, VIBE and TSE T2 
weighted sequence. 
Note: Only crucial parts of catheters are depicted in the curved course of the vessel.  
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Catheter type Sequence type 
    FLASH 2D    FLASH 3D        VIBE 
 
   TSE 
   T2 weighted 
4F straight Alta 
Flow Premium 
catheter 
(Optimed, 
Germany) 
    
4F pigtail like 
Alta Flow 
Premium 
catheter 
(Optimed, 
Germany) 
    
 
 
 
 
 
 
 
 
 
 
Table 8  
4F straight and pigtail shaped Alta Flow Premium catheter (Optimed, Germany) in the aorta 
shaped phantom filled with saline and 1% Gd-BOPTA (Multihance, Bracco, Milan, Italy) 
solution. FLASH 2D, FLASH 3D, VIBE and TSE T2 weighted sequence. 
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Catheter type Sequence type 
     FLASH 2D     FLASH 3D          VIBE 
 
    TSE  
    T2 weighted 
4F straight Alta 
Flow Premium 
catheter 
(Optimed, 
Germany) 
    
4F pigtail like 
Alta Flow 
Premium 
catheter 
(Optimed, 
Germany) 
    
 
 
 
 
 
 
 
 
 
 
Table 9 
4F straight and pigtail like Alta Flow Premium catheters (Optimed, Germany) in the vessel 
phantom (Elastrat, Geneva, Switzerland) filled with saline and 1% Gd-BOPTA (Multihance, 
Bracco, Milan, Italy) solution. FLASH 2D, FLASH 3D, VIBE and TSE T2 weighted sequence. 
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Catheter type Sequence type 
     FLASH 2D     FLASH 3D          VIBE 
 
    TSE  
    T2 weighted 
Progreat 
microcatheter 
2.4F (Terumo, 
Japan) 
    
Progreat 
microcatheter 
2.7F (Terumo, 
Japan) 
    
Cantata 
microcatheter 
2.8F (Cook 
Medical, USA) 
    
 
 
 
 
 
Table 10 
Progreat microcatheter 2.4 and 2.7F (Terumo, Japan) and Cantata microcatheter 2.8F 
(Cook Medical, USA) in a aorta shaped phantom filled with saline and 1% Gd-BOPTA 
(Multihance, Bracco, Milan, Italy) solution. FLASH 2D, FLASH 3D, VIBE and TSE T2 
weighted sequence. 
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Catheter type Sequence type 
   FLASH 2D   FLASH 3D      VIBE 
 
   TSE 
   T2 weighted 
5F Cobra 100 
cm (Cook 
Medical) 
    
4F Straight  65 
cm (Cook 
Medical) 
    
4F Pigtail 65 
cm (Cook 
Medical) 
    
5F Sidewinder 
100 cm (Cook 
Medical) 
    
5F Shepard 
Hook 65 cm 
(Cook Medical) 
    
Table 11  
5F cobra 100 cm, 4F straight 65 cm, 4F pigtail 65 cm, 5F sidewinder 100 cm, 5F shepherd 
Hook 65 cm (Cook Medical, USA) in a aorta shaped phantom filled with saline and 1% Gd-
BOPTA (Multihance, Bracco, Milan, Italy) solution. FLASH 2D, FLASH 3D, VIBE and TSE 
T2 weighted sequence. 
 
57 Part 1: MR safety of interventional instruments and their validation in vascular... 
 
 
 
 
V.3.4 Conclusions 
The catheters with hydrophilic coating (Cobra, Terumo) show no susceptibility artifact 
in any of the four tested sequences. The Optimed company offers a promising solution with 
excellent visibility of non-braided straight and pigtail shaped catheters. Microcatheters 
(Terumo) with 2.4F and 2.7 F diameters showed also MR compatibility with good image 
depiction. The lack of susceptibility artifacts proves that no metallic parts are being integrated 
into the catheters. Therefore, these catheters are considered MR safe. Other regular 
catheters are excluded from the second part of the study since they may pose a potential risk 
to the tissue due to potential RF heating. In addition, their image artifacts make them 
unsuitable for MR guided interventions.  
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VI. PART 2: EVALUATION OF LIVER TUMOR PERFUSION BY INTRAARTERIAL 
TRANSCATHETER MAGNETIC RESONANCE ANGIOGRAPHY DURING 
TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR 
CARCINOMA 
 
VI.1 Materials and Methods 
VI.1.1 Study design 
This prospective study was performed in the Clinic of Diagnostic and Interventional 
Radiology at Saarland Medical Center in Homburg in Germany from the 29.02.2012 to 
04.12.2012. The angiographies were performed on an Artis live and Artis zee angiography 
devices (Siemens Medical, Erlangen, Germany). The magnetic resonance imaging was 
performed on 1.5 T Aera MR Scanner with 70 cm diameter wide bore (Siemens Medical, 
Germany). All patients participating in the study signed the informed consent at least one 
night prior to the procedure. The local ethics committee approved this prospective study.   
 
VI.1.2 Patients  
The cohort consisted of 27 patients (21 men, median age 61 years old). A total of 62 
TACE procedures with i.a. contrast agent application in MR were performed. The cohort was 
divided into two subgroups. The first subgroup encompassed 9 patients, in this subgroup 
overall 13 TACE procedures were performed. In these patients different contrast agent 
concentrations (from 0.5% to 10.0%) were applied during MR examination. The results of this 
qualitative analysis allowed us to determine the appropriate contrast agent concentration for 
the procedures in the second, larger subgroup. Detailed description of analysis is provided in 
the chapter VI.1.5. The second subgroup consisted of 18 patients in whom 49 TACE 
procedures were performed. Here, the selected contrast agent concentration was injected 
and two GE sequences were applied. Detailed description of quantitative analysis is provided 
in the chapter VI.1.6. 
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 Overall, a single TACE procedure was performed in 10 patients, in the remaining 17 
patients multiple TACE procedures were conducted. The detailed characteristics of the 
patients are summarized in Table 12. All patients were qualified for TACE either as palliative 
or bridging approach before liver transplantation during a multidisciplinary conference. 
Inclusion criteria were in line with the latest European guidelines and were as follows (EASL: 
European Association For The Study Of The Liver; EORTC: Organisation For Research And 
Treatment Of Cancer clinical practice guidelines: management of hepatocellular carcinoma 
(21)): age more than 18 years old, Child Pugh class A or B, focal or multifocal HCC, no 
contraindication against MR imaging (i.e., pacemaker, metal implants, claustrophobia), 
signed informed consent. Exclusion criteria were uncorrectable coagulopathy (Quick < 50%) 
or thrombocytopenia (< 50 000/ ul), serum creatinin level >2 mg/Dl, complete portal vein 
thrombosis of the main trunk, Child Pugh class C, life expectancy less than 6 months and 
lack of informed consent. Patients with thrombosis of only one branch of the portal vein were 
enrolled in the study. One patient with cholangiocellular carcinoma (CCC) was enrolled in the 
study but due to the progression of the disease after TACE was qualified for systemic 
chemotherapy. One patient with liver metastases of colon carcinoma and one with 
metastases of urothelial carcinoma of the bladder were also included in the study after 
revising the indications during the weekly tumor board conference. The diagnosis of HCC 
was mostly performed by contrast enhanced CT, sonography or MR scan according to well-
established perfusion patterns. A total of 5 patients underwent a biopsy to confirm the 
diagnosis. Detailed clinical characteristics are provided in Table 13. 
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Patients 
characteristics 
 
 
Number of patients 
Number of TACE 
procedures 
27  
62  
Age (median) 
       (range) 
61 years old  
35-86 years old 
Gender:  6 females 
21 males 
Prior treatment 8 TACE 
4 Resection 
2 RFA 
1 SIRT 
Diagnosis of HCC 21 MR 
5 Biopsy  
1 CT 
 
 
 
 
 
 
 
 
Table 12 Patients characteristics. 
Abbreviations: 
TACE, transarterial chemotherapy; RFA, 
radiofrequency ablation; SIRT, selective 
internal radiation therapy; MR, magnetic 
resonance; CT, computed tomography 
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Clinical characteristics Number of 
patients 
Tumor type  
 HCC 24 
 CCC 1 
 Metastases 2 
Right liver lobe 17 
Left liver lobe 4 
Bilobar 6 
Portal vein branch thrombosis 3 
Cirrhosis 24 
Cause of liver cirrhosis  
 Alcohol 8 
 Hepatitis C virus 7 
 Hepatitis B virus 4 
 Unknown 2 
 Alfa 1 antritripsin                     
deficiency 
1 
 Haemochromatosis 1 
 Autoimmune                  
hepatitis 
1 
Child- Pugh score 
in patients with liver cirrhosis  
(N = 24) 
 
 
 A 17 
 B 7 
Table 13 Summary of clinical characteristics 
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VI.1.3 Procedure details and workflow  
Procedure details 
Every procedure began with local anesthesia (2% Mepivacain) applied after shaving 
the right groin and draping the patient in sterile fashion. Then the right common femoral 
artery was punctured with 18G needle (Terumo, Tokyo, Japan) and a 5F or 6F sheath 
(Radifocus, Japan) was inserted over a 0.89 mm hydrophilic GW (Terumo, Tokyo, Japan) 
using the modified Seldinger technique. The celiac trunk and hepatic artery were cannulated 
using the previously tested 4F/5F cobra or sidewinder shaped catheters with hydrophilic 
coating (Terumo, Tokyo, Japan). The smaller caliber branches of hepatic arteries were 
cannulated using the 2.4F -2.9F microcatheters (Progreat, Terumo, Tokyo, Japan). DSA was 
performed either manually or automatically (2 ml/s) with iodinated contrast agent (Imeron 
300, Bayer Schering Pharma, Berlin, Germany) to confirm the correct therapy position of the 
catheter. In cases when the therapy position was difficult to estimate, for example due to 
multiple tumors or lack of tumor visualization, the catheter was left in the main trunk of right 
or left hepatic artery. After removing all metal and non-MR compatible objects from the 
angiography table, the patients were transferred into the MR unit in order to perform MR 
angiography (details of MR procedure in chapter VI.1.4). Afterwards the patient was 
transferred back to the angiography unit and the catheter position was confirmed by X-ray. 
The chemotherapy (5 to 7 ml of Lipiodol (Lipiodol Ultra Fluide, Guerbet, Villepinte, France) -
oily iodinated contrast agent and 50 mg Doxorubicin in 10 ml 0.9% NaCl) was applied via 
catheter or microcatheter in the therapy position. Then the catheters and sheath were 
removed and angio-seal closure system was applied. A native CT scan one day after the 
procedure was performed to determine the distribution of the lipiodol. Antiemetic (4 mg 
Ondansetron), analgesic (50 mg Pethidinhydrochloride) and corticosteroids (250 mg 
Prednisolon) were administered intravenously in 250 ml NaCl bolus prior to application of 
chemotherapy.  
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Workflow 
As previously described (Chapter III.2, interventional MR scanners, Figure 1) the 
angiography suite and MR suite were separated by a 3.7 meters wide corridor and equipped 
with sliding doors between them. The patients were transferred from the angiography table to 
the MR unit and then moved over a rolling board on the MR table. The contrast agent injector 
with specially diluted Gadolinium- 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid 
(Gd-DOTA) (0.5-10.0% in first group and 5.0% in second group) (Dotarem, Guerbet, 
Villepinte, France) were prepared before the procedure. The patient already draped in sterile 
fashion at the beginning of the procedure was covered with sterile drapes and then the MR 
coil was placed (eight channel body matrix coil, Siemens Medical, Erlangen, Germany). 
Sterile plastic tube with contrast agent was connected to the distal part of the catheter. After 
placing the headphones and emergency bell the MR examination proceeded. Localizers 
were used to plan the following sequences: two GE sequences (detailed description in the 
chapter VI.1.4) were performed one after another and the contrast agent was injected twice 
(once per sequence) via the catheter in the hepatic artery. The 3D volume interpolated GE 
(VIBE) was performed as the first sequence in 22 patients whereas in 27 patients SPGR 
(FLASH 3D) was performed as the first sequence.  Duration times of every procedure-related 
event were collected and analyzed in order to determine the effectiveness and to optimize 
the workflow for the future iMRI approaches.  
 
VI.1.4 MR imaging protocol 
The spatial coverage of the whole liver was provided. All images were obtained using 
the eight channel body matrix coil (Siemens Medical, Erlangen, Germany). All sequences 
were performed in parallel imaging technique and integrated parallel acquisition technique 
GRAPPA (Generalized Autocalibrating Partially Parallel Acquisition) with factor 2 was used in 
every sequence. At first, the baseline imaging without contrast agent administration in 3D 
VIBE and SPGR FLASH 3D were performed. Then the contrast enhanced sequences were 
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performed in the following phases: arterial, portalvenous and late venous phase. The 
parameters of these sequences are summarized in Table 14. The contrast agent 
(Gadolinium DOTA, Dotarem, Guerbet, Villepinte, France) was applied automatically via 
catheter in the hepatic artery with 2 ml/s flow rate and followed by injection of 10 ml of 0,9% 
NaCl. The settings of the automated contrast agent injector are summarized in Table 15. In 
the first 9 patients and 13 examinations the contrast agent concentration varied from 0.5% to 
10.0% in NaCl. The next 18 patients and 49 procedures followed the protocol with 5.0% 
dilution of gadolinium.  
 
Sequence 
type 
 
Slice 
orientation 
 
TR 
ms 
TE 
ms 
FA 
(⁰) 
Matrix 
(mm) 
ST 
(mm) 
GRAPPA*  
 
VIBE 
 
axial 3.22 1.24 12 320/160 2 2 
 
Flash 3D 
 
axial 2.78 1.07 25 512/112 1.6 2 
Table 14 Sequence parameters.  
* integrated parallel acquisition technique: GRAPPA; Generalized Autocalibrating Partially 
Parallel Acquisition  
 
 
Contrast agent 
 
 
Volume  
overall 
Flow rate Concentration Time of injection 
Gd-DOTA 20 ml 2 ml/s 
0.5 - 10.0% - 13 procedures 
 
5.0% - 49 procedures 
10 seconds 
Table 15 Contrast agent parameters. 
 
VI.1.5 Qualitative analysis 
Aim of this descriptive analysis was to estimate the optimal contrast agent 
concentration for the MR angiography during TACE. First 13 procedures in 9 patients were 
performed with different MR contrast agent concentrations (from 0.5% to 10.0%) applied via 
the catheter in the hepatic artery. These examinations served to estimate the optimal 
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concentration of applied Gd-DOTA for the best image quality. Two radiologist blinded to the 
contrast agent concentration evaluated all images independently in 13 first examinations 
using a dedicated questionnaire with four questions concerning image quality and gaining 
potential information due to i.a. transcatheter in MR angiography. The image quality 
questions are summarized in detail in the Table 16. The additional information as 
confirmation of complete tumor targeting, additional tumor vascularization from another 
branch, tumor depiction possible only in MRI due to inconclusive angiography, detection of 
new lesions with MR contrast enhancement (metastases/ high grade dysplastic nodules), 
were also evaluated. 
The FLASH 3D and VIBE sequences with different concentrations of Gd-DOTA 0.5%, 
1.0%, 1.5%, 2.5%, 3.0%, 5.0% and 10.0% were performed only in the arterial phase. Every 
sequence in every procedure was evaluated and placed in the scale from best to worst in the 
questionnaire. The scoring system is presented in the Table 16. Due to the low number of 
patients in this subgroup a statistical analysis of differences between two applied sequences 
was not performed.  
 
Image quality question 
 
 
Scoring for every question 
 
1. Depiction of perfused liver segment 
2. Depiction of tumor vs. perfused liver segment 
3. Depiction of tumor vs. non perfused liver segment 
4. Presence of catheter artifact in the vessels 
[yes/no] 
The very best one: 3 points 
The middle one: 2 points 
The acceptable one: 1 point 
Poor image quality: 0 points 
Table 16 Scoring system for qualitative analysis. 
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VI.1.6 Quantitative analysis  
Aim of this analysis was to determine image quality of obtained sequences in 
transcatheter intraprocedural MR angiography with application of 5.0% Gd-DOTA during 
TACE. For this purpose the quality parameters like SNR and CNR were evaluated. The 
comparison of SNR in the phase of maximal tumor enhancement, SNR of the whole tumor, 
SNR of the unenhanced liver and CNR of the tumor (maximum enhancement) to normal liver 
as well as CNR whole tumor to normal liver of the two applied GE sequences were 
performed using non-parametric Mann Whitney test (significance at P levels < 0.05). The 
follow up of the tumor enhancement in MR image was analyzed in 9 patients who underwent 
three or more consecutive TACE with i.a. transcatheter MR angiography. Signal parameters 
in 18 patients and 49 TACE procedures with i.a. transcatheter liver tumor perfusion in MR 
angiography were analyzed. Statistical tests were performed using the Version 5.03 of Graph 
Pad Prism software (GraphPad Software Inc. La Jolla, CA, USA). Benefits resulting from i.a. 
transcatheter contrast agent application in MR angiography during TACE namely: 
confirmation of complete tumor targeting, additional tumor vascularization from another 
branch, tumor depiction possible only in MRI due to inconclusive angiography, detection of 
new lesions with MR contrast enhancement (metastases/ high grade dysplastic nodules) 
were evaluated. 
 
VI.1.6.1 Signal parameter assessment  
The signal parameters were assessed in all examinations with 32-bit Osirix Imaging 
Software DICOM viewer, using region of interest (ROI) analysis.  
Before obtaining contrast enhanced MR scans by VIBE and FLASH 3D sequences, 
an unenhanced scan of each sequence was performed twice for the subsequent subtraction 
and calculation of background noise. The standard deviation (SD) in ROI placed in the tumor 
(in the region of maximal enhancement as well as in the point of maximal axial tumor 
diameter) and liver parenchyma on subtracted unenhanced image were considered as an 
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image noise for the lesion and normal liver parenchyma. The ROI placed in the tumor and 
liver parenchyma on contrast enhanced images and their mean pixel values were considered 
as signal intensity (SI). The SI in the tumor was measured in the region of maximal 
enhancement as a mean value of three consecutive measurements. The SI was also 
obtained for the whole tumor and was measured in the place of maximal axial tumor 
diameter. The integrated parallel imaging technique used in our MR scanner was GRAPPA 
and the accelerator factor of 2 was applied. The “g” factor was not explicitly calculated due to 
complex coils sensitivity maps and noise correlation matrix, which were not available. The 
SNR and CNR were calculated as follows (62).  
 
 
 
 
 
 
 
 
 
 
 
SI, Signal intensity; SD, Standard deviation  
 
SNR  region of max. tumor enhanc.=
                                    √ 
                   
 
SNR  whole tumor=
                 √ 
                   
 
SNR  liver =
          √ 
                   
 
CNR  whole tumor/liver=
                 √ 
                   
 −  
         √ 
                   
 
CNR  point of max. tumor enhanc./liver=
                                    √ 
                   
 −  
         √ 
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VI.2 Results 
 
VI.2.1 Results of workflow analysis  
 Table 17 presents each event registered, their average duration in minutes (Mean ± 
SD), maximum and minimum values. 
Events 
 
Mean ( ± SD) (min.) Max (min.) Min (min.) 
Access to the groin 7.55 ( ± 7.92) 30 2 
Cannulation of the tumor vessel 42.22 ( ± 21.46) 110 6 
Transfer to MRI suite 11.09 ( ± 6.86) 31 2 
Time in MRI 15.78 ( ± 6.43) 40 7 
Transfer to angiography suite 9.15 ( ± 6.35) 25 2 
Cannulation after MRI (in case of 
another therapy position or catheter 
dislocation) 
19.21 ( ± 22.21) 105 1 
TACE 26.38 ( ± 17.46) 85 5 
Table 17 Average duration of every event during TACE with i.a. transcatheter  MR 
angiography. 
 
 
 A delay in transferring the patient from the angiography suite to the MRI area was 
observed in the 71.19% of the cases due to the occupation of the MRI by patients scheduled 
for a diagnostic MRI. The average waiting time before transferring the patient was of 20.68 (± 
19.91) minutes with a maximum waiting time of 80 minutes.  
 Overall, the TACE procedure is divided in 3 blocks: a first part in the angiography 
suite, the second part in the MRI area and the third part describes the TACE procedure back 
in the angiography suite. Table 18 shows the average, maximum and minimum times for 
each phase of the procedure. 
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Phase 
 
Mean ( ± SD) (min.) Max (min.) Min (min.) 
First: angiography 53.73 ( ± 24.35) 124 15 
Second: MRI 28.22 ( ± 11.84) 80 7 
Third: angiography 50.93 ( ± 26.32) 146 13 
 Table 18 Times recorded for every phase of the TACE with i.a. transcatheter MR 
angiography. 
 
 
 The times presented in Table 18 do not take into account the waiting times for MRI in 
case of delay.  
 
VI.2.2 Results of qualitative analysis: 5.0% as the optimal concentration of gadolinium in 
FLASH 3D and VIBE sequences 
Results of qualitative analysis of two applied sequences are demonstrated in Tables 
19 and 20. The optimal concentration allowing the best depiction of perfused liver segment 
as well as the best depiction of tumor versus perfused  and non-perfused liver segment was 
5.0% in both sequences used. The lower concentration of the contrast agent prohibited sharp 
tumor delineation, especially in large tumor masses. The 10.0% concentration did not allow 
good tumor delineation either, due to similar signal intensity of the tumor and surrounding 
liver tissue. Additional information gained by i.a. contrast agent application in MR allowed to 
avoid two incomplete tumor embolizations. In one patient one new lesion (second HCC) was 
discovered, which was not diagnosed by regular MRI after intravenous (i.v.) contrast 
enhanced MR scan. All additional information is summarized in Table 21.  
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 Concentration of Gd-DOTA in FLASH 3D 
Image quality question 0.5% 1.0% 1.5% 2.5% 3.0% 5.0% 10.0% 
1. Depiction of perfused liver segment 0 5 0 4 0 13 0 
2. Depiction of tumor vs. perfused liver 
segment 
0 0 0 8 0 1 0 
3. Depiction of tumor vs. non perfused 
liver segment 
0 0 5 6 0 11 0 
4. Presence of catheter artifact in the 
vessels [yes/no] 
no no no no no no no 
Points overall 0 5 0 18 0 25 5 
Table 19 Different concentrations of Gd-DOTA during FLASH 3D sequence. The points were 
calculated by subjective judgment of two radiologists according to the scoring system 
(chapter VI.1.5). 
 
 
 Concentration of Gd-DOTA in VIBE 
Image quality question 0.5% 1.0% 1.5% 2.5% 3.0% 5.0% 10.0% 
1. Depiction of perfused liver segment 0 0 0 0 0 3 2 
2. Depiction of tumor vs. perfused liver 
segment 
0 0 0 0 0 11 5 
3. Depiction of tumor vs. non perfused 
tumor segment 
0 0 0 0 0 11 1 
4. Presence of catheter artifact in the 
vessels [yes/no] 
no no no no no no no 
Points overall 0 0 0 0 0 25 8 
Table 20 Different concentrations of Gd-DOTA during VIBE sequence. The points were 
calculated by subjective judgment of two radiologists according to the scoring system 
(chapter VI.1.5). 
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Additional information due to 
intraprocedural MRI with intraarterially 
administerd contrast agent 
Number of examinations N = 13 
1. Confirmation of complete tumor targeting 
(primary uncorrected catheter position) 
11 examinations (85%) 
 
2. Additional tumor vascularization from 
another branch  
2 examinations (15%) 
 
3. Delineation of necrotic areas in the tumor  6 examinations* (46%) 
 
4. Tumor depiction only in MRI, inconclusive 
angiography 
3 examinations* (23%) 
 
5. Detection of new lesions with MR contrast 
enhancement (metastases/ high grade 
dysplastic nodules) 
1 examination* (8%)  
Table 21 Additional information due to i.a. transcatheter MR angiography during TACE in 
first 13 examinations.  
*- delineation of necrotic tumor areas as well as tumor depiction only in MRI and detection of 
new lesions can occur simultaneously in more than 1 procedure. 
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VI.2.3 Results of quantitative analysis  
 
SNR MEASUREMENTS: 
 
VIBE yields higher SNR in the region of maximal tumor enhancement compared to 
FLASH 3D  
SNR tumor measured in the region of maximal tumor enhancement was higher in 
images acquired by VIBE sequence; this was true for arterial, portalvenous and late venous 
phases (p values 0.02, 0.01 and 0.002, respectively). The results are demonstrated in in 
Figures 12 - 14. 
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Figure 12 SNR in the region of maximal tumor 
enhancement in FLASH 3D in arterial phase (median: 21.36, 
min: 7.79, max: 50.11) and VIBE sequence (median: 36.96, 
min: 9.92, max: 91.54) in the arterial phase. *p < 0.05 
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Figure 13 SNR in the region of maximal tumor 
enhancement in FLASH 3D in portalvenous phase 
(median: 20.25, min: 5.50, max: 57.87) and VIBE 
sequence (median: 28.59, min: 10.48, max: 83.89) in 
portalvenous phase.*p < 0.05 
 
 
Figure 14 SNR in point of maximal tumor enhancement in 
FLASH 3D in late venous phase (median: 16.19, min: 
5.83, max: 51.03) and VIBE sequence (median: 24.37, 
min: 10.21, max: 72.28) in the late venous phase.  
*p < 0.05 
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VIBE yields higher SNR compared to FLASH 3D measured in the whole tumor 
The assessment of SNR in the whole tumor (defined as maximal axial diameter, 
including perfused and not perfused necrotic areas) in the arterial, portalvenous and late 
venous phase demonstrated that the SNR of the VIBE sequence is higher compared to 
FLASH 3D sequence (p values: 0.01, 0.005 and 0.0004, respectively). The results are 
demonstrated in Figures 15 - 17. 
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Figure 15 SNR in the whole tumor in FLASH 3D in arterial 
phase (median: 19.14, min: 7.80, max: 49.57) and VIBE 
sequence (median: 29.73, min: 9.61, max: 81.61) in the 
arterial phase. *p < 0.05 
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Figure 16 SNR in the whole tumor in FLASH 3D in 
portalvenous phase (median: 19.45, min: 5.66, max: 54.39) 
and VIBE sequence (median: 28.34, min: 11.85, max: 
82.53) in the portalvenous phase. *p < 0.05 
 
 
Figure 17 SNR in the whole tumor in FLASH 3D in late 
venous phase (median: 15.95, min: 3.71, max: 48.57) and 
VIBE sequence (median: 23.03, min: 10.54, max: 73.91) in 
the late venous phase. *p < 0.05 
 
 
76 Part 2: Evaluation of liver tumor perfusion by intraarterial transcatheter magnetic...  
  
 
 
 
 
VIBE yields higher SNR in the unenhanced liver compared to FLASH 3D 
The SNR in unenhanced liver revealed significant differences between FLASH 3D 
and VIBE sequences in all applied phases with p < 0.0001, yielding a higher SNR for the 
VIBE sequence. The results are demonstrated in Figures 18 - 20. 
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Figure 18 SNR in the liver in FLASH 3D in arterial phase 
(median: 9.48, min: 5.72, max: 18.34) and VIBE sequence 
(median: 18.16, min: 7.61, max: 48.76) in the arterial phase. 
*p < 0.05 
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Figure 19 SNR in the liver in FLASH 3D in portalvenous 
phase (median: 9.28, min: 5.45, max: 19,43) and VIBE 
sequence (median: 17.74, min: 7.58, max: 50.12) in the 
portalvenous phase. *p < 0.05 
 
 
 
 
Figure 20 SNR in the liver in FLASH 3D in late venous 
phase (median: 9.27, min: 4.47, max: 18.12) and VIBE 
sequence (median: 17.75, min: 7.89, max: 46.81) in the late 
venous phase. *p < 0.05 
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Comparison of SNR between the region of maximal tumor enhancement and the whole 
tumor yielded no statistically significant differences either in VIBE or in FLASH 3D 
sequence 
SNR comparison between the region of maximal tumor enhancement and the whole 
tumor (defined as maximal axial diameter) showed no statistical differences. The comparison 
was conducted separately for FLASH 3D and VIBE sequence. In FLASH 3D sequence, the p 
values for arterial phase equaled 0.54, for portalvenous phase 0.65 and for late venous 
phase 0.64. In VIBE sequence, the p values for arterial phase equaled 0.39, for portalvenous 
phase 0.89 and for late venous phase 0.84.  The results are presented in Tables 22 and 23. 
 
VIBE sequence SNR in the region of max. 
tumor enhancement 
SNR in the whole tumor 
Phase   
Arterial 36.96 [9.92 - 91.54] 29.73 [9.61 - 81.61] 
Portalvenous 28.59 [10.48 - 83.89] 28.34 [11.85 - 82.53] 
Late venous 24.37 [10.21 - 72.28] 23.03 [10.54 - 73.91] 
Table 22 Results of SNR (region of max. tumor enhancement versus whole tumor) in VIBE 
sequence. SNR values are presented as medians and ranges. 
 
 
FLASH 3D sequence SNR in the region of max. 
tumor enhancement 
SNR in the whole tumor 
Phase   
Arterial 21.36 [7.79 - 50.11] 19.14 [7.80 - 49.57] 
Portalvenous 20.25 [5.50 - 57.87] 19.45 [5.66 - 54.39] 
Late venous 16.19 [5.83 - 51.03] 15.95 [3.71 - 48.57] 
Table 23 Results of SNR (region of max. tumor enhancement versus whole tumor) in FLASH 
3D sequence. SNR values are presented as medians and ranges. 
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CNR MEASUREMENTS: 
Contrast to noise ratio in the region of maximal tumor enhancement/liver reveals no 
statistically significant differences between VIBE and FLASH 3D sequences 
The CNR between the region of maximal tumor enhancement and tumor-free liver 
demonstrated no significant differences between FLASH 3D and VIBE sequences in any of 
the applied phases (p = 0.51 for arterial phase, p = 1.0 for portalvenous phase and p = 0.69 
for late phase). The results are given in Table 24. 
 
 
Phase 
 
 
 
CNR in region of maximal tumor enhancement/liver  
 VIBE FLASH 3D 
Arterial 16.11 [0.84 - 65.23] 10.96 [0.65 - 41.35] 
Portalvenous 9.86 [0.50 - 54.65] 11.96 [0.08 - 38.43] 
Late venous 6.30 [0.46 - 54.10] 7.03 [0.48 - 32.90] 
Table 24 Results of CNR (region of max. tumor enhancement versus tumor-free liver) in 
VIBE and FLASH 3D sequences. CNR values are presented as medians and ranges. 
 
 
Contrast to noise ratio of the whole tumor/liver reveals no statistically significant 
differences between VIBE and FLASH 3D sequences 
The CNR between the whole tumor enhancement (defined as maximal axial 
diameter) and tumor-free liver demonstrated no significant differences between FLASH 3D 
and VIBE sequences in none of the applied phases (p = 0.60 for arterial phase, p = 0.63 for 
portalvenous phase and p = 0.94 for late phase). The results are presented in Table 25. 
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Phase 
 
 
 
CNR in the whole tumor/liver  
 VIBE FLASH 3D 
Arterial 14.74 [0.21 - 55.30] 10.41 [0.72 - 40.81] 
Portalvenous 8.94 [1.04 - 58.99] 10.57 [0.25 - 36.22] 
Late venous 6.85 [0.15 - 51.07] 6.77 [0.97 - 30.44] 
Table 25 Results of CNR (whole tumor versus tumor-free liver) in all phases in VIBE and 
FLASH 3D sequences. CNR values are presented as medians and ranges. 
 
 
Comparison between CNR of the region of maximal tumor enhancement/tumor-free 
liver and CNR of the in whole tumor/tumor-free liver reveals no statistically significant 
differences neither in VIBE nor in FLASH 3D sequence 
Comparison of CNR values calculated for the region of maximal tumor enhancement 
and the whole tumor each time correlated to the tumor-free liver demonstrated no statistically 
significant difference. The calculation was done within one sequence and identical perfusion 
phases. In FLASH 3D sequence, the p values for arterial phase equaled 0.62, for 
portalvenous phase 0.67 and for late venous phase 0.83. In VIBE sequence, the p values for 
arterial phase equaled 0.51, for portalvenous phase 0.97 and for late venous phase 0.88.  
The results are presented in Tables 26 and 27. 
 
VIBE sequence CNR in the region of max. 
tumor enhancement/liver 
CNR in the whole 
tumor/liver 
Phase   
Arterial 16.11 [0.84 - 65.23] 14.74 [0.21 - 55.30] 
Portalvenous 9.86 [0.50 - 54.65] 8.94 [1.04 - 58.99] 
Late venous 6.30 [0.46 - 54.10] 6.85 [0.15 - 51.07] 
Table 26 Results of CNR (region of max. tumor enhancement versus whole tumor) in VIBE 
sequence. CNR values are presented as medians and ranges. 
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FLASH 3D sequence CNR in the region of max. 
tumor enhancement/liver 
CNR in the whole 
tumor/liver 
Phase   
Arterial 10.96 [0.65 - 41.35] 10.41 [0.72 - 40.81] 
Portalvenous 11.96 [0.08 - 38.43] 10.57 [0.25 - 36.22] 
Late venous 7.03 [0.48 - 32.90] 6.77 [0.97 - 30.44] 
Table 27 Results of CNR (region of max. tumor enhancement versus whole tumor) in FLASH 
3D sequence. CNR values are presented as medians and ranges. 
 
 
VI.2.4 Follow up and MR angiography benefits 
 
Follow up of SNR in the whole tumor (defined as maximal axial diameter) 
demonstrates its decrease in consecutive procedures 
The follow up of the tumor enhancement in MR image was analyzed in those patients, 
who underwent three or more TACE with i.a. transcatheter MR angiography. This was the 
case in nine patients. Three patients underwent four consecutive TACE procedures and in 
this group SNR in the whole tumor was decreasing from one procedure to the next. In one 
patient however the SNR decreased after the first TACE and then increased in the next two 
procedures. Six patients underwent three consecutive TACE procedures. In this group of 
patients the SNR of the whole tumor were decreasing or remained equal. Detailed 
characteristics of the patients, their lesions and procedures are presented in Table 28. The 
results of the analysis are presented in Figures 21 and Figure 22. No statistical calculations 
were done due to the small number of patients available for the analysis. 
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Patient’s  
number 
Prior TACE 
treatments 
before 
inclusion into 
the study 
HCC characteristics in the 
beginning of the TACE 
therapy at the point of 
inclusion in the study 
Group (I: four 
consecutive TACE 
procedures, II: three 
consecutive TACE 
procedures) 
1 1 TACE  Multilocular, bilobar (two 
nodules)  
I 
2 2 TACE  Multilocular (two nodules in 
right liver lobe) 
I 
3 none Unilocular in right liver lobe I 
4 3 TACE  Unilocular in watershed 
distribution in the right liver lobe 
II 
5 2 TACE  Unilocular in the left liver lobe II 
6 None Multilocular lesion in the right 
liver lobe 
II 
7 None Unilocular in right liver lobe and 
multiple dysplastic nodules 
II 
8 2 TACE  Multilocular, bilobar  (two in 
right and one in left liver lobe) 
II 
9 None Unilocular in left liver lobe II 
Table 28 Characteristics of patients and their HCC lesions who underwent three or more 
consecutive TACE procedures. Patient’s numbers are not consistent with the order of entry 
into the study.    
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Figure 21 SNR of the whole tumor in three 
patients who underwent four consecutive 
TACE procedures. 
Figure 22 SNR of the whole tumor in six 
patients who underwent three consecutive 
TACE procedures.  
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Additional information gained by transcatheter intraarterial liver tumor perfusion in 
MR angiography during transarterial chemoembolization 
Additional information obtained during transcatheter intaarterial MR angiography 
performed in 49 procedures is in detail summarized in Table 29. In 86% of procedures (n = 
42) the primary catheter position was judged to be correct due to observed entire tumor 
perfusion in MRI. The necrotic tumor areas were demarcated in 29 among of 42 
examinations, mostly in patients with multiple TACE procedures performed. In 7 
examinations (14%) the primary catheter position had to be revised to achieve better tumor 
targeting: in four procedures as consequence of additional arteries supplying the tumor (8%), 
in three procedures as consequence of suboptimal primary catheter position (2%) or contrast 
enhancement of the gallbladder (4%). New lesions (HCC-metastases or high grade 
dysplastic nodules) were discovered in three MR TACE procedures; these were not included 
in the group with suboptimal primary catheter position. The example of a difficult tumor 
location is presented in Figures 23 - 26. In this patient the tumor enhancement was readily 
identified under fluoroscopy after contrast agent application via the left hepatic artery (Figure 
23). The additional vascularization from the branches of the right hepatic artery could not be 
detected by DSA. Contrast enhanced FLASH 3D sequence (Figure 24 and 25) 
demonstrated that approximately 2/3 of the tumor was supplied by the left hepatic artery and 
1/3 by the right hepatic artery. Figure 26 is the native CT scan showing complete tumor 
targeting after TACE with lipiodol being performed via both hepatic arteries. The examples of 
a potentially malignant new HCC lesion are presented in Figures 27-30.  
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Additional information due to 
intraprocedural MRI with intraarterially 
administered contrast agent 
Number of examinations N = 49 
1. Confirmation of complete tumor targeting 
(primary uncorrected catheter position) 
42 examinations (86%) 
 
2. Additional tumor vascularization from 
another branch  
4 examinations (8%) 
 
3. Suboptimal therapy position 
(Gallbladder enhancement, false liver 
segment) 
3 examinations (6%) 
 
4. Delineation of necrotic areas in the tumor  
 
29 examinations* (59%) 
 
5. Tumor depiction only in MRI, inconclusive 
angiography 
3 examinations* (6%) 
 
6. Detection of new lesions with MR contrast 
enhancement (metastases/ high grade 
dysplastic nodules) 
3 examinations* (6%)  
Table 27 Benefits of MR angiography in 18 patients and all together 49 examinations.  
*Delineation of necrotic tumor areas as well as tumor depiction only in MRI and detection of 
new lesions can occur simultaneously in more than 1 procedure. 
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Figure 23  
DSA image of the HCC in liver segment 4 (arrows) 
after injection of iodized contrast agent via the left 
hepatic artery.  
Figure 24  
HCC in liver segment 4 (black arrow) depicted during 
a FLASH 3D after application of Gd-DOTA via 
catheter in the left hepatic artery, not enhanced rim of 
the tumor (white arrow) as hint for additional arterial 
supply from another vessel.  
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Figure 25  
HCC in liver segment 4 depicted during a FLASH 3D 
after application of Gd-DOTA via catheter in the right 
hepatic artery: previously non enhanced rim of the 
tumor demonstrates  contrast enhancement (black 
arrow).  
Figure 26  
Lipiodol retained within the HCC in liver segment 4 
(black arrow) on a native CT scan one day after 
TACE with application of chemotherapy and lipiodol 
via both hepatic arteries.  
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Figure 27  
New HCC lesion in segment 6 of the liver (black 
arrow) after intraarterial contrast agent application in 
the arterial phase.  
Figure 28  
New HCC lesion in segment 6 of the liver (black 
arrow) after intraarterial contrast agent application in 
the portal venous phase with washout phenomenon.  
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Figure 29  
The same HCC lesion as in Figures 28-29 in 
segment 6 of the liver (black arrow) after i.v. contrast 
agent application in regular MR scan in the arterial 
phase. 
Figure 30 
The same HCC lesion as in Figures 28-29 in 
segment 6 of the liver (black arrow) after i.v. contrast 
agent application in regular MR scan in the portal 
venous phase. Please note the differences between 
washout phenomenon after the intraarterial and i.v. 
contrast application.  
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VII. DISCUSSION 
 
VII.1 PART 1: MR safety of interventional instruments and their validation in vascular 
models 
According to FDA (Food and Drug Administration) or CEN (European Committee of 
Standardization), as well as ISO (International Organization of Standardization) MR safety 
and compatibility are recognized as a relevant issue in production of medical instruments. 
Despite the fact that standardized methods of testing medical devices already exist (i.e 
ASTM: American Society of Testing and Materials), the number of MR safe devices on the 
market is sparse. Several investigations in animal models and involving limited cohorts of 
patients (44, 72) demonstrated the feasibility and effectiveness of glass fibers embedded in 
epoxy resin, organic polymers like PEEK or fiberplastics. A newly published study by Bell et 
al. (4) describes passive and active navigation possibilities of a MR compatible Kevlar-made 
GW. The diameter of this wire (1.4 mm”) is however too large for standard catheters so its 
potential practical application possibilities are limited. Three German companies (Epflex, 
Dettingen, MaRVis, Aachen, and Andramed, Reutlingen) already offer the prototypes of MR 
compatible GWs. However by the time of our study none of them received the CE marking 
(Conformité Européenne) hence their use in patients was not allowed and further studies 
were necessary. Epflex and MaRVis GWs, the only ones available to us, present similar 
lengths and diameters compared to standard GWs and are in the preclinical research phase. 
These novel GWs prototypes were employed in the first part of the study. 
  
Heating experiments with standard and MR compatible guidewires 
The first prototypes of an Epflex GW were already tested in animal trials (40, 41), 
however their potential heating in 1.5 T MR scanner has not been investigated. Therefore, in 
the first experiment with an aorta phantom the potential heating of the Epflex GW prototype 
was compared with the regular nitinol GW. It is already well documented that nitinol-based 
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wires exposed to radiofrequency energy during an MR experiments can produce heating due 
to their conductive properties (13, 42, 56). Our results confirm that the nitinol GW 
demonstrated the temperature elevation in GE sequences. Therefore we used this GW as a 
reference in our heating measurements. In our study we focused on imitating the scenario of 
the MR guided endovascular intervention. Because the GW position depends on the patients 
anatomy and the type of the endovascular procedure, we put the phantom in two different 
positions in the scanner: in isocenter and as far off-center as possible. The first position 
could imitate the interventions performed on the aorta, renal arteries or vena cava. The latter 
one is mostly used in approaches on peripheral femoral or tibial vessels. Furthermore, 
positioning the GW in off-center position induces more likely heating due to applied 
radiofrequency pulses and thus SAR levels. Minor increase of temperature of nitinol GW, like 
in isocenter position, should not injure the thick vessel wall of the aorta. The resonance 
phenomenon occurrence is however difficult to predict since it depends also on many 
environmental factors (for example body mass or temperature of the patient) and sudden, 
unexpected temperature increase of nitinol-based GW has to be taken into consideration. 
Moreover the temperature is more likely to increase in occluded or stenotic vessels and such 
scenario is to expect in patients with atherosclerosis. As demonstrated by Konings (42) at al. 
the presence of stenosis can increase the RF heating and may result in elevation of the GW 
temperature to 80°C. In our study, the nitinol GW in the off-center position of the aorta 
phantom in the scanner demonstrated substantial increase of the temperature of 9.6° for 
bSSFP and of 13° for SPGR sequence. It has to be taken into account that the first sequence 
was run only for 60 seconds and considering the steep increase and shape of the curve 
(Figure 4), the temperature probably would most likely increase even more with longer 
sequence duration. Epflex prototype GW minor temperature elevation of 0.1 - 0.4°C in both 
experiments is comparable with the temperature elevation of the reference probe attached to 
the MR table and was in the range of measurement variations. A single measurement point 
at the tip of the both GWs and lack of human shaped phantom were minor drawbacks of the 
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study. Especially the latter one is important because the size of the object in the MR field 
influences the B0 (static magnetic) and B1 (RF induced) fields. These limitations however 
were overcome in the next study with Thiel-embalmed human cadaver. 
The next investigation on Thiel-embalmed cadaver was performed to mimic the 
conductivity of the human body.  In this study it was possible to simulate the liquid flow in the 
left femoral artery with 0.9% saline solution, which has also similar conductivity to the human 
blood. The GW in the MR field acts like dipole antenna and electric currents translocate 
along the wire forming standing waves (42). This resonance phenomenon is dependent on 
the length of the GW and its position in MR field (42). The length of the GW determines if the 
waves can be reflected by the ends of such wire (42). Of note, 23 cm is the shortest GW 
length capable of producing resonance phenomena at 64 megahertz (MHz) in 1.5 T (48). 
Hence our standard nitinol GW with 150 cm was long enough to induce heating during MR 
measurements. In order to find and induce such resonance, we changed the GW position in 
MR field by retracting the GW 2 cm every 10 seconds. The retraction did not influence the 
temperature of nitinol GW by more than 2°. Even long scan times did not influence the 
temperature. In such scenario the saline flow also did not demonstrate any “cooling effect”. In 
one previous study (13) it was demonstrated that sparks were produced when the GW end 
touched the bare animal skin. We were not able to replicate this observation in our 
experiment despite touching the skin of the cadaver, probably due to the resonance 
conditions. Limitations of the study include the single measurement point at the distal tip of 
the GW. The placement of such wire with the probe causes however extreme technical 
difficulties and has to be performed very carefully in order not to harm the cadaver vessel.  
 
Artifact size of a new MR compatible guidewire prototype depends on time to echo (TE) 
under gradient echo sequences  
These experiments were conducted with a novel MR compatible GW from MaRVis 
Company. The GW we used was in the phase of preclinical experiments at the time of the 
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study and tests of its passive visualization in a 1.5 T scanner was desirable. In the MaRVis 
GW iron markers are incorporated into the shaft of the wire and its depiction is based on their 
susceptibility artifacts. The artifacts size depends strongly on the type of the sequence. Spin 
echo (SE) sequences are prone to cause fewer artifacts than GE sequences (45, 47). In our 
experiment we chose the SPGR sequence (FLASH) since this sequence can be used for 
near real time imaging applied in MR guided procedures. Minimizing the echo time, 
increasing matrix and the slice thickness play a role in decreasing the susceptibility artifacts 
(60). The artifact size is important when performing interventional endovascular procedures 
especially in vessels of smaller caliber. Using a TE of 10 or 20 ms the tip marker of the wire 
was no longer distinguishable from the other markers and its artifact obscured the whole 
renal artery. This was true for both tested GW types (flexible and stiff one). In our 
investigation the GWs were also depicted in the aorta lumen, which had an inner diameter of 
2.5 cm. In this case the artifacts were also present, but due to the larger vessel lumen, the 
wire was clearly visible in the aorta and did not mask the vessel walls. We confirmed that 
with shorter echo times the small-sized susceptibility artifacts allowed good depiction of the 
device inside the 5 mm lumen vessel, rendering the sequence with the lowest TE of 1.07 ms 
the most suitable for depicting the MaRVis GW.  
 
Passive visualization of catheters in a vascular model  
The endovascular devices, like catheters, pose specific features as elasticity, kinking 
resistance, radiopacity and differently shaped tips. Metal mesh from stainless steel (braiding) 
contributes to the rigidity and detectability by fluoroscopy. As explained before (Chapter 
III.4.2) this metal grid may also contribute to potential excessive heating during MR imaging. 
It is difficult to predict which catheter or what part of it is coveredd with the mentioned metal 
and how it will influence the magnetic field, since this information is mostly not available on 
the vendor website or instruction manual. On this account we have tested the catheters that 
are most commonly used in our angiography suite. Two phantoms, one purchased and 
94 Discussion 
  
 
 
 
 
founded by the IIIOS project, were used. In the first phantom, where the catheters were 
inserted into a glass-made aorta, almost the entire shafts of the catheters could be explored 
and evaluated. The vessel phantom of the left lower extremity (Elastrat, Geneva, 
Switzerland) enabled the “closer look” at the catheter tips in good resolution. The catheters 
used in the clinical part of the study and considered MR safe showed no artifact during MRI. 
Catheters with metal components that are hazardous for the patient due to potential RF 
heating, were identified by susceptibility artifacts and on this account no longer taken into 
consideration during clinical part. Catheters with the hydrophilic layer (Terumo, Tokyo, 
Japan) demonstrated no metal mesh and no artifacts. They are not always the first choice 
during regular TACE procedures due to their softer shaft and potential instability. These 
features however facilitated their introduction into hepatic arteries without causing vessel 
spasms. Other instruments like intravascular sheaths were also tested in the MR 
environment, their length (i.e., 10 cm) however is considered not hazardous to present 
resonant effects (76) even in off center position in the scanner. According to antenna theory 
(33, 48) a shortest wire length acquired for resonance at 64 MHz corresponding to main 
magnetic field of 1.5 T is 23 cm. Furthermore, the introducer sheaths contained no metallic 
parts. 
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VII.2 PART 2: Evaluation of liver tumor perfusion by intraarterial transcatheter 
magnetic resonance angiography during transarterial chemoembolization in patients 
with hepatocellular carcinoma  
Depending on the stage of the disease, TACE can be considered either as palliative 
or bridging therapy before liver transplantation, since it can reduce the tumor size (21). 
Indeed, the previous study of Takayasu et al. (68) conducted in over 8,000 patients treated 
with TACE demonstrated that median survival rate was 34 months in good responders. 
Another investigation conducted in 104 HCC patients revealed even higher median survival 
rates of 48.6 months (14). Delivery of the chemoembolic agents into the entire HCC is the 
main goal of TACE and is one of the main factors underlying the efficacy of this procedure 
(46). Concerning the good life expectancy, the best achievable tumor targeting is desirable. 
According to the literature (29, 47, 75) integrating MR into TACE enables monitoring the 
therapy and helps to determine the optimal catheter position. Our patient cohort 
encompasses 62 TACE procedures combined with MR imaging is to date the largest 
reported in the literature. During our prospective study we performed several analysis in 
order to optimize and evaluate the possible benefits of MRI for depiction of i.a. liver tumor 
perfusion during TACE.  
 
Workflow 
TACE, which is performed under fluoroscopy control, consists of several different 
steps and in our study was additionally complemented by MR imaging. Standard MR 
examination times depend on the examined anatomy and the sequences used and take 
approximately 30 to 60 minutes. To minimize the prolongation of the TACE procedure we 
performed only two diagnostic MRI sequences. We observed, that the “bottleneck” of the 
procedure was however not the MR scanning itself, but the waiting time for the MR scanner, 
when the catheter was placed in the therapy position. Although TACE patients were always a 
priori scheduled for MR examination, an accurate start time of the procedure was difficult to 
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predict since the cannulation of the tumor-supplying vessel under fluoroscopy is different in 
every TACE. Data analysis revealed that an average MR scan time was 15 minutes. In one 
case the scanning time was prolonged to 40 minutes due to a software error, which has to be 
taken into consideration when planning future procedures. In conclusion, MR imaging 
integrated into TACE prolonged the regular procedure time of about 35 minutes. The waiting 
period directly before the MR examination may be eliminated in centers with MR scanner 
destined for interventional procedures only. The combination of TACE with intraprocedural 
MRI is however troublesome in the every-day routine. This might be further aggravated by 
emergency cases requiring an MR examination. Consequently, the patients have to wait with 
the inserted sheath and catheter outside the MR scanner, what can potentially increase the 
risk of infection. This drawback on the other hand is outweighing by the benefits of the 
procedure like detection and correction of suboptimal catheter positions. Of note, no 
procedure-related complications were observed. 
 
Qualitative analysis 
The sequences applied in the evaluation of tumor perfusion in MR were both T1 
weighted GE sequences. Both sequences are regularly used for MR examinations after i.v. 
contrast agent application. The gadolinium concentrations and flow rates applied i.a. were 
different from the regular i.v. applications and were tailored to the caliber of the vessel. In our 
investigation the flow rate of contrast agent was always 2 ml/s to avoid vessel injury and 
backwards flow of the contrast agent. The dilution of contrast agent of 20.0% reported by 
other authors (29) was according to our analysis too high for the selective catheter position in 
the liver. Although the gadolinium is a safe option even in patients with impaired renal 
function (55) its amount should be reasonably restricted. Several contrast agent 
concentrations were tested in the first patients subgroup with 13 procedures. Our qualitative 
analysis demonstrates that even the minimal 0.5% concentration was sufficient to delineate 
the tumor itself, however in cases of multiple lesions localized in more than one liver 
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segments the concentrations below 5.0% were insufficient to reliably depict all tumor 
masses. The contrast agent concentrations of 0.5%, 1.0%, 1.5%, 2.5% and 3.0% were 
seldom rated as those of acceptable quality (see Table 24 and 25). Surprisingly, the 
concentration of 10.0% was not the best one either due to lack of contrast between the 
enhanced tumor and liver segment. The limitation of this analysis was the low number of 
procedures in this subgroup. Another issue is the different tumor morphology in the 
examined 9 patients; not every concentration was tested in all different tumor types. 
Nonetheless, we judged a concentration of 5.0% Gd-DOTA to be ideal for further studies of 
hepatic artery perfusion, since it demonstrated a superior quality. As expected, no catheter 
artifacts were observed in any of the used sequences since all inserted catheters were tested 
in our previous experiments.  
 
Quantitative analysis 
Quantitative analysis was performed in a second group of 18 patients with 49 TACE 
procedures. In all cases 5.0% concentration of the contrast agent was applied in three 
phases: arterial, portalvenous and late venous phase. It is disputable if the portalvenous 
phase in our study corresponds to the regular portal venous phase acquired after i.v. contrast 
agent injection. The acquisition time in regular MR liver examination is approximately  
60 - 70 s after i.v. injection. In our study the portal venous phase was acquired 30 - 40 s after 
i.a. application of contrast agent at the latest. However, in all cases the HCC typical washout 
(5, 34, 37, 52, 69) of contrast agent was observed. Three phases performed one after 
another allowed us to observe the tumor perfusion as a dynamic process.  
The SNR in the region of maximal tumor enhancement as well the SNR of the whole 
lesion were significantly higher in the VIBE sequence in all perfusion phases compared to the 
FLASH sequence. Moreover the VIBE in contrast to FLASH 3D sequence preserves wide 
anatomic coverage of the organs of the upper abdomen, maintaining adequate spatial 
resolution at the same time. On the other hand, the acquisition time were longer for the VIBE 
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sequence compared to the FLASH 3D (approximately 18 vs.11 seconds), but still within the 
margin of an easy breathe hold for the patient.  The SNR measured in the liver demonstrated 
significant differences showing a better signal for the VIBE sequence. Even native MR scans 
of the liver before contrast agent application demonstrated the higher signal intensity of the 
liver compared to FLASH 3D. This can be explained by general macroscopically higher 
signal intensity of the unenhanced liver tissue in patients with liver cirrhosis in VIBE 
sequences. No statistically relevant differences were found between the SNR in point of 
maximal tumor enhancement and in the whole tumor. Most of our patients underwent 
multiple TACE approaches so the lesion enhancement patterns varied between consecutive 
procedures.  
Contrast to noise ratios defined as the difference between SNR of the tumor and SNR 
of the liver related to noise demonstrated no significant differences between FLASH 3D and 
VIBE sequences either. This was true for both SNR measurements in the region of maximal 
tumor enhancement and in the whole tumor. In our opinion this could be due to the relatively 
small sample number. Of note, small tumors (<3cm) in multifocal HCC demonstrated the 
tendency of homogenous enhancement in contrast to larger lesions where multiple local 
necrotic areas were observed. The so-called ”pseudocapsule”, which is characteristic for 
well-differentiated HCC (2 patients), was not included into the ROIs due to its very thin 
coating. The differences between lesions morphology in several patients could also have an 
influence on signal intensities.  
All MR scans were performed in transverse plane in order to achieve the best lesion 
depiction and to save time. In none of the sequences artifacts of the catheter were observed. 
Usually, only the part of the catheter localized in the hepatic artery was depicted. The 
catheter was recognizable after contrast agent injection due to the high signal intensity along 
the shaft. This can be explained by positive contrast principle of the T1 shortening contrast 
agent. Of note, the visualization of the catheter hindered the quality in none of the acquired 
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images. In both sequences (VIBE and FLASH 3D) clear tumor delineation was possible in 
good resolution and quality. 
 
Follow up and benefits of intraaterial MR angiography 
The combination of MR imaging with interventional radiology procedures offers a 
unique possibility of therapy monitoring and treatment planning. As demonstrated in Figures 
23 - 25 the simultaneous tumor supply from left and right hepatic artery might impede the 
treatment, especially in tumors in watershed distributions. The DSA image however imitates 
complete tumor perfusion after injection of contrast agent via the left hepatic artery due to the 
nature of its projection technique. TACE performed via the left hepatic artery would cause 
incomplete tumor targeting. In other published studies, the primary catheter position had to 
be revised in 25% (46) and in 40% (74) of procedures. The three-dimensional image 
acquisition is thereby crucial in estimation of adequate catheter position. Newer X-ray 
techniques integrated into a fluoroscopy unit might be also able to overcome the 
disadvantage of a DSA projection technique. 
In our investigation we changed the catheter position in order to better target the HCC 
only in 14% of procedures. Overall, 5 patients already had undergone previous TACE 
therapy before inclusion in the study. This factor might have led to an improved primary 
catheter position for optimal tumor targeting in these patients. On the other hand, atypical 
recruitment of collaterals from the phrenic artery for example might only occur after treatment 
of the primary arterial supply to the tumor. Properly performed imaging prior to the procedure 
(CT/MRI) represents a pivotal determinant for the outcome of TACE. This can yield the 
necessary anatomical information needed for correct positioning of the catheter. Identification 
of new lesions, which demonstrated, apart from i.a. contrast uptake, also washout 
phenomenon, is an advantage of i.a. MR imaging observed during our study. These lesions 
presented only contrast uptake in the arterial phase in the regular MR scan performed prior 
the TACE and were classified as dysplastic nodules. Overall, it was the case in four 
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procedures (taking both subgroups into account). Considering their imaging features after i.a. 
contrast agent application they might be classified as potential HCC. Perfusion morphology 
of detected additional lesions after i.a. application of contrast agent might be however 
different from the one after i.v. application. Previously mentioned washout may occur due to 
shunts between the HCC and normal liver parenchyma. Nonetheless, the detection of new 
lesions might alter further therapy and such newly detected tumors should be further 
classified with a short-term follow-up MRI scan. One explanation for the lack of detection 
during standard MRI is that lesions in an early stage might be detectable only after selective 
i.a. application of contrast agent due to their small size and the better contrast uptake. 
Dynamic perfusion changes like washout in the portalvenous or late venous phase are highly 
suggestive of additional HCC lesions despite the fact that the perfusion dynamic after i.a. 
application of gadolinium is not a well-established method in classification of HCC. The 
literature clearly states that non-invasive diagnostic criteria in cirrhotic patients are indeed 
based on four-phase multidetector CT or dynamic contrast enhanced MR scans, but after i.v. 
contrast media application (5, 34, 37, 53, 69). Typical hallmarks of HCC like arterial 
hyperenhancement and venous washout are regarded as determinants of this type of tumors 
only in lesions larger than 2 cm present in the cirrhotic liver. In lesions with diameter below 2 
cm, the nodule showing arterial contrast uptake must not necessarily be a HCC (27). The 
prospective study by Forner et al. (27) evaluated recently the accuracy of contrast-enhanced 
ultrasound together with MRI and fine needle biopsy for the diagnosis of the nodules smaller 
than 2 cm in the cirrhotic livers. The authors stated that the HCC in these cases might be 
established without a biopsy when both techniques are consistent and conclusive. The 
sensitivity of such criteria was however only 33%, because absence of malignant hallmarks 
does not exclude malignancy (27). In such cases close surveillance is recommended and 
this should be adapted to small nodule detected after i.a. contrast media application as well. 
The detection of HCC suspected lesion was the case in four patients in our study; these 
lesions were seen in standard MR examination as well, but due to a lack of washout they 
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were not categorized as malignant. The first patient suffered primarily from well-differentiated 
HCC in watershed distribution in segment 4 of the liver. He was included in the study after 
his first selective TACE treatment. The suspected lesion was identified as unclear contrast 
enhancement in i.a. MR angiography in the segment 6, showed however no clear washout in 
the late phases. The lesion measured initially 1.7 cm and was treated with chemoembolizing 
agent since the second TACE.  In the follow-up MR examination the lesion was still classified 
as dysplastic nodule of the same size since the washout phenomena were absent. The 
TACE treatment of the lesion was this time impossible due to heavy vessel spasms. The next 
follow-up MR examination demonstrated the lesion of 1.9 cm (0.2 cm size progress) but still 
no washout. In i.a. MR angiography washout was this time however readily visible and the 
lesion was also treated with chemotherapy. However the changes in perfusion seen over 
time could in theory also be due to treatment effects. In the next follow-up MR the washout 
was eventually visible and the lesion was classified as another HCC, the size however was 
this time even lesser than initially (1.3 cm) (Figures 27-30). Eventually, this patient became a 
liver transplantation. The second patient suffered from well distinguishable singular HCC in 
the segment 6 of the liver with 5 small (<1.2 cm) lesions disseminated in the right liver lobe, 
mostly in segments 5 and 6. They were classified in the baseline MR examinations with i.v. 
contrast agent administration as dysplastic nodules since they demonstrated only strong 
arterial enhancement and did not show any washout in the portalvenous phase. In our study 
during TACE they were not readily depicted in the DSA image, probably due to small size. 
After i.a. contrast agent administration in the MR angiography examination they were 
however easily identified, one of them demonstrated moreover a washout phenomenon. All 
lesions were under treatment due to non-selective application of chemotherapy into the right 
liver lobe. In the next follow-up MR examinations the same lesion classified previously as 
dysplastic nodule showed eventually a washout and was classified as HCC lesion. Size of 
the lesions was not progressive. It is unclear why the lesion demonstrated typical hallmarks 
after chemoembolizing treatment and therefore it remains disputable, if this lesion is a HCC. 
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The third patient suffered from the recurrent HCC in the right liver lobe after left 
hemihepatectomy. By the time she was included in the study she suffered from 6 HCC 
lesions with the typical washout phenomena described in regular follow-up MR examination 
(1 day before TACE treatment).  By the time of i.a. MR angiography all 6 lesions were readily 
depicted with typical HCC hallmarks and one small 1 cm nodule with washout phenomena 
was additionally depicted in segment 8. In the follow-up examination (5 weeks after TACE) 
this particular lesion demonstrated the washout phenomena and strong suspicion of new 
HCC. All lesions in this particular case showed inhomogeneous response pattern and the 
newly formed HCC in segment 8 demonstrated no size progress during next follow-up 
examinations. The fourth patient suffered from singular HCC located subcapsular in segment 
8 of the liver. One other lesion (<1 cm in segment 7) without washout was diagnosed and 
classified as dysplastic nodule in the baseline MR examination. The i.a. MR angiography 
demonstrated at least two already centrally necrotic lesions <1 cm (liver segment 7 and 6) 
with marginal contrast enhancement but no washout. In the follow-up examination in about 5 
weeks the lesions showed washout, which was debatable due to their small size below 1 cm, 
washout was however readily visible in i.a. MR angiography. Yet in 3 months follow-up 
multiple new HCC satellites metastases or newly formed HCC lesions were detectable in 
both liver lobes. In this case despite the selective and non-selective application of the 
chemoembolizing agent to the liver, TACE was not a successful method of treatment. 
Second imaging technique (contrast enhanced CT or sonography) was not employed in any 
of the patients. Like described above i.a. MR angiography seems to be very sensitive in 
detecting small HCC lesions, even under 1 cm size, but the histopathological correlation is 
required.  
Most of the patients qualified for multiple TACE therapy. Three patients involved in 
our study underwent four consecutive procedures. Two of the patients demonstrated 
decrease of SNR measured in the whole tumor, most certainly due to good tumor targeting 
and developed necrotic areas within the tumor as consequence of therapy. However, in one 
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patient with multifocal HCC in the right liver lobe this was not the case. His treatment 
response was not equal in every lesion. Revascularization in one HCC satellite lesion was 
observed every single time in control MRI after TACE despite multiple treatments while other 
lesions showed no perfusion, i.e., were necrotic. On the other hand the native CT scan 
performed after TACE demonstrated the proper lipiodol distribution in all HCC lesions. 
Another six patients included in the study underwent three consecutive procedures. In these 
cases SNR of the whole tumor either remained the same or demonstrated the decrease 
expected, due to ischemic tumor areas. It is interesting to observe that especially those 
patients without prior TACE treatment showed a clear decrease in SNR. 
Limitations of combining DSA and MRI are the prolonged procedure time of about 35 
minutes and relocation of the patients from angiography room, which may potentially pose an 
increased infection risk. Therefore, we had decided not to measure the MR perfusion in the 
targeted lesion right after completing TACE like other authors (46, 75). Indeed, the native CT 
scan as gold standard allowed evaluating the lipiodol distribution in the targeted liver 
segment one day after procedure. Recently evaluated cone beam CT employed during 
TACE demonstrates similar success rates compared to intraprocedurel MRI (70). Its pivotal 
advantage is better image resolution and demarcation of vessels as well as no need of 
moving the patient during the procedure. High radiation dose as well as difficulties in 
separation of stained (i.e., from previous TACE procedures) lipiodol in the tumor with the 
newly applied one are the disadvantages. Furthermore, no additional detection of unknown 
lesions has been reported by cone beam CT. Cone beam CT was at the beginning of the 
study not available in our institution.  
In conclusion, i.a. liver tumor perfusion in magnetic resonance angiography during 
TACE is feasible and safe for the patients. This method allows the detection of incorrect 
catheter location so that the therapy position may be easily revised yielding a better therapy 
result. Moreover it might contribute to improved therapy outcome due to early diagnosis of 
new developed potentially malignant lesions.  
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